Michael Kupinski, Director of Research, Equity Research Analyst, Digital, Media & Technology , Noble Capital Markets, Inc.
Jacob Mutchler, Research Associate, Noble Capital Markets, Inc.
Refer to the full report for the price target, fundamental analysis, and rating.
Shareholders approve CEO option grant. Travelzoo shareholders approved a 600,000-share non-qualified stock option grant to CEO Holger Bartel, formalizing a performance-based compensation structure tied directly to stock price appreciation and marking a clear inflection point in management incentives. The grant represents a significant 5.5% of the current total shares outstanding.
Structure emphasizes near-term performance and meaningful upside. The options carry a $5.05 exercise price, vest semi-annually over two years, and have a five-year term, creating a relatively short execution window in which management must deliver results to realize value.
Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.
This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).
*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.
ST. PETERSBURG, Fla., April 20, 2026 (GLOBE NEWSWIRE) — Superior Group of Companies, Inc. (NASDAQ: SGC) (the “Company”) today announced that it will release the results of its operations for the first quarter 2026 before the market open on Monday, May 4, 2026. Michael Benstock, Chairman and Chief Executive Officer, and Mike Koempel, President and Chief Financial Officer, will host a teleconference at 8:00 am Eastern Time that day to discuss the Company’s results.
The live webcast and archived replay can be accessed in the investor relations section of the Company’s website at https://ir.superiorgroupofcompanies.com/presentations. Interested individuals may also join the teleconference by dialing 1-844-861-5505 for U.S. dialers and 1-412-317-6586 for international dialers. The Canadian toll-free number is 1-866-605-3852. Please ask to join the Superior Group of Companies call.
A telephone replay of the teleconference will be available through May 11, 2026. To access the replay, dial 1-855-669-9658 in the United States and Canada or 1-412-317-0088 from international locations. Please reference conference number 4789430 for replay access.
About Superior Group of Companies, Inc. (SGC): Established in 1920, Superior Group of Companies is comprised of three attractive business segments each serving large, fragmented and growing addressable markets. Across Healthcare Apparel, Branded Products and Contact Centers, each segment enables businesses to create extraordinary brand engagement experiences for their customers and employees. SGC’s commitment to service, quality, advanced technology, and omnichannel commerce provides unparalleled competitive advantages. We are committed to enhancing shareholder value by continuing to pursue a combination of organic growth and strategic acquisitions. For more information, visit www.superiorgroupofcompanies.com.
CHICAGO, April 20, 2026 (GLOBE NEWSWIRE) — FreightCar America, Inc. (NASDAQ: RAIL), a diversified manufacturer of railroad freight cars, today announced that it will release its first quarter 2026 financial results on Monday, May 4, 2026, after the market close, and host a teleconference to discuss its first quarter 2026 results on the following day. Teleconference details are as follows:
Please note that the webcast is listen-only and webcast participants will not be able to participate in the question and answer portion of the conference call. Interested parties are asked to dial in approximately 10 to 15 minutes prior to the start time of the call.
An audio replay of the conference call will be available beginning at 3:00 p.m. (Eastern Time) on Tuesday, May 5, 2026, until 11:59 p.m. (Eastern Time) on Tuesday, May 19, 2026. To access the replay, please dial (844) 512-2921 or (412) 317-6671. The replay passcode is 13760024. An archived version of the webcast will also be available on the FreightCar America Investor Relations website.
About FreightCar America
FreightCar America, headquartered in Chicago, Illinois, is a leading designer, producer and supplier of railroad freight cars, railcar parts and components. We also specialize in railcar repairs, complete railcar rebody services and railcar conversions that repurpose idled rail assets back into revenue service. Since 1901, our customers have trusted us to build quality railcars that are critical to economic growth and instrumental to the North American supply chain. To learn more about FreightCar America, visit www.freightcaramerica.com.
Two of the most dominant component suppliers in the recreational vehicle and outdoor enthusiast markets may be on the verge of combining. Patrick Industries (NASDAQ: PATK) and LCI Industries (NYSE: LCII) — both headquartered in Elkhart, Indiana — confirmed on April 17 that they are in active discussions regarding a potential merger of equals. Bloomberg first reported the deal would be structured as an all-stock transaction.
The announcement, delivered via separate press releases after Friday’s market close, sent LCI’s trading volume to nearly 3.8 times its 20-day average — a clear signal that the market is treating this as a high-conviction event.
The strategic logic is straightforward. Patrick Industries, founded in 1959, manufactures and distributes component products for the RV, marine, powersports, and housing markets. The company operates more than 190 facilities across a portfolio of over 85 brands and employs more than 10,000 people. LCI Industries, through its Lippert Components subsidiary, is a global leader in engineered components for outdoor recreation and transportation markets, with over 140 manufacturing and distribution facilities across North America, Africa, and Europe.
These are not two fringe players. Together, they supply a substantial portion of the infrastructure that goes into RVs, marine vessels, and powersports units built across North America. A combined entity would carry significant scale advantages — from raw material procurement and logistics to technology investment and aftermarket distribution. As of April 17, Patrick carried a market cap of approximately $3.54 billion and LCI sat at roughly $3 billion. A successful all-stock merger would create an outdoor recreation supply chain player worth approximately $6.5 billion.
The timing is deliberate. The RV industry has been navigating a post-pandemic normalization cycle, with unit shipments softening from their 2021 highs. Consolidation at the supplier tier is a rational response — two companies with overlapping market footprints, shared OEM customers, and comparable operational infrastructure have more to gain together than competing independently. The potential synergies are tangible: combined purchasing power, reduced overhead duplication across facilities, stronger pricing leverage with customers, and a platform large enough to accelerate investment in connected vehicle and smart RV technology.
Historically, LCI has grown through bolt-on acquisitions of product lines and smaller businesses. A merger of equals with Patrick would represent a significant departure from that playbook — a transformational combination rather than incremental expansion. For Patrick, it would provide immediate global distribution reach through Lippert’s international footprint, something the company would otherwise take years to build organically.
There are still material unknowns. No definitive agreement has been signed. Both companies stated they will not comment further until a formal deal is announced or discussions are terminated. Regulatory review of a transaction this size would also be expected, given the combined company’s market share across several RV and marine component categories.
For investors in small and mid-cap industrials, this is a developing story with real consequences for the outdoor recreation supply chain. If Patrick and LCI formalize this combination, it would stand as one of the more significant sector realignments of 2026 — and a signal that the Elkhart manufacturing corridor is entering a new phase of consolidation.
No assurance of a transaction has been given. Watch for an 8-K filing or formal press release for the next material development.
NEW YORK–(BUSINESS WIRE)– Perfect Corp. (NYSE: PERF) (“Perfect” or the “Company”), a leading artificial intelligence (“AI”) company offering AI and augmented reality (“AR”) powered solutions to beauty, fashion, photo and video creative industries, today announced that the independent special committee (the “Special Committee”) of the Company’s board of directors (the “Board”), formed to evaluate and consider the previously announced preliminary non-binding proposal letter dated March 18, 2026 (the “Proposal”), has selected Kroll LLC. as its financial advisor and DLA Piper as its international legal counsel.
The Special Committee is continuing its review and evaluation of the Proposal. The Board cautions its shareholders and others considering trading in its securities that neither the Board nor the Special Committee has made any decision with respect to the Proposal. There can be no assurance that any definitive offer will be received, that any definitive agreement will be executed relating to the transaction contemplated by the Proposal, or that the transaction contemplated by the Proposal or any other similar transaction will be approved or consummated. The Company does not undertake any obligation to provide any updates with respect to any transaction, except as required under applicable law.
About Perfect Corp.
Founded in 2015, Perfect Corp. is a leading AI company offering self-developed AI- and AR- powered solutions dedicated to transforming the world with digital tech innovations that make your virtual world beautiful. On Perfect’s direct consumer business side, Perfect operates a family of YouCam consumer apps and web-editing services for photo, video and camera users, centered on unleashing creativity with AI-driven features for creation, beautification and enhancement. On Perfect’s enterprise business side, Perfect empowers major beauty, skincare, fashion, jewelry, and watch brands and retailers by supplying them with omnichannel shopping experiences through AR product try-ons and AI-powered skin diagnostics. With cutting-edge technologies such as Generative AI, real-time facial and hand 3D AR rendering and cloud solutions, Perfect enables personalized, enjoyable, and engaging shopping journey and helps brands elevate customer engagement, increase conversion rates, and propel sales growth. Throughout this journey, Perfect maintains its unwavering commitment to environmental sustainability and fulfilling social responsibilities. For more information, visit https://ir.perfectcorp.com/.
Forward-Looking Statements
This communication contains forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended, or the Exchange Act, that are based on beliefs and assumptions and on information currently available to Perfect. In some cases, you can identify forward-looking statements by the following words: “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing,” “target,” “seek” or the negative or plural of these words, or other similar expressions that are predictions or indicate future events or prospects, although not all forward-looking statements contain these words. Any statements that refer to expectations, projections or other characterizations of future events or circumstances, including strategies or plans, are also forward-looking statements. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievements to be materially different from those expressed or implied by these forward-looking statements. These statements are based on Perfect’s reasonable expectations and beliefs concerning future events and involve risks and uncertainties that may cause actual results to differ materially from current expectations. These factors are difficult to predict accurately and may be beyond Perfect’s control. Forward-looking statements in this communication or elsewhere speak only as of the date made. New uncertainties and risks arise from time to time, and it is impossible for Perfect to predict these events or how they may affect Perfect. In addition, risks and uncertainties are described in Perfect’s filings with the Securities and Exchange Commission. These filings may identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Perfect cannot assure you that the forward-looking statements in this communication will prove to be accurate. There may be additional risks that Perfect presently does not know or that Perfect currently does not believe are immaterial that could also cause actual results to differ from those contained in the forward looking statements. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by Perfect, its directors, officers or employees or any other person that Perfect will achieve its objectives and plans in any specified time frame, or at all. Except as required by applicable law, Perfect does not have any duty to, and does not intend to, update or revise the forward-looking statements in this communication or elsewhere after the date of this communication. You should, therefore, not rely on these forward-looking statements as representing the views of Perfect as of any date subsequent to the date of this communication.
STAFFORD, Texas, April 20, 2026 (GLOBE NEWSWIRE) — Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the “Company”), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating Fast Track designated GLSI-100, an immunotherapy to prevent breast cancer recurrences, today presents the published abstract and poster from the AACR Meeting 2026.
The abstract is shown below and the poster being presented today can be seen and downloaded at the bottom of Phase III clinical trial tab on the Company’s website here.
This is the first abstract and poster presented jointly with the Steering Committee of FLAMINGO-01 with statistically significant delayed-type-hypersensitivity (DTH) immune response data, with subgroup analysis by the most prevalent HLA types.
In the non-HLA-A*02 open label arm where all patients (n=247) were treated with GLSI-100, immune responses to GP2 were measured at baseline and over time using skin tests and other methods. The other methods will be presented at a future conference.
A DTH reaction (redness and/or induration) was used to assess in vivo immune responses in patients. The DTH orthogonal mean was also measured 48-72 hours after injection but is not reported here.
In this preliminary data analysis, there was a significant increase in percentage of patients experiencing a DTH reaction (redness) in month 4 or month 6 compared to baseline. There were 191 patients with both baseline and month 4 or 6 assessments.
The frequency of DTH reactions increased by approximately 4x (290%) in the total open-label non-HLA-A*02 population, increasing from 5.2% of the patients experiencing a DTH reaction at baseline, prior to any GLSI-100 administration, to 20.4% of the patients experiencing a DTH reaction in month 4 or month 6 (McNemar, p < 0.001).
As reported in Table 1 of the poster, each HLA-A type exhibited more frequent immune reactivity after treatment with GLSI-100 than at baseline with frequency increasing from 100% to 700%.
Baseline DTH reaction prior to any treatment suggests that GP2 may be a natural antigen and that GP2 specific T cells may exist in some patients prior to any treatment with GLSI-100. Baseline immune response to GP2 prior to any vaccination with GP2 was also observed in the Phase IIb trial and is being observed in the blinded randomized arms of FLAMINGO-01, where HLA-A*02 only patients are being vaccinated.
Mechanism of Action: A positive immune response is an indicator that the immune system has been activated against recurring cancer cells, potentially leading to the prevention of metastatic breast cancer. The Company previously announced that in the non-HLA-A*02 arm, a preliminary analysis of recurrence rates after the Primary Immunization Series (PIS) is completed shows an approximately 70-80% reduction in recurrence rate. Thus, the immune response data is supporting the mechanism of action that reduces recurrences and prevents metastatic breast cancer.
This statistically significant non-HLA-A*02 open label arm immune response data is trending similarly to the immune response data in the HLA-A*02 patients in the Phase IIb study and the HLA-A*02 arms of FLAMINGO-01. The study is ongoing and data collection and cleaning continue, while some patients may still be in their PIS vaccination phase, so final results may vary.
A 1% per year recurrence rate is so low that the number of recurrence events is too few to correlate a negative or lack of immune response to recurrence. The same constraint existed with the Phase IIb data which has a similarly low recurrence rate per year. While DTH immune response may be valuable at an aggregate level looking at whole patient populations, the recurrence rate is too low to validate any immune response measure as a biomarker for individual patient treatment decisions. It is also likely that some responding patients may not exhibit any immune response but still could be protected by GLSI-100 vaccination, thus helping to preserve the blind on the randomized arms of FLAMINGO-01.
The immune response abstract and poster conclusion: The statistically significant increase in the incidence of DTH reactions over time found in this preliminary analysis of GLSI-100 treated non-HLA-A*02 patients shows that GLSI-100 treatment should not be limited to HLA-A*02 patients. Patients treated with GLSI-100 were increasingly able to mount an immune response to GP2 as evidenced in this preliminary data. Future investigations may explore the use of immune responses to assess correlation of DTH to ISRs, immunogenicity of GLSI-100 by specific HLA type, timing of boosters to sustain immunity, clinical site performance, and the discontinuation of treatment for non-responders.
In addition, the second poster describing the Phase III trial design, which is being presented on Tuesday, April 21, can be downloaded and seen on the website using the same link. This poster provides an update that over 1,300 patients have been screened to date in FLAMINGO-01. The new protocol amendment, which is still under regulatory review in certain countries, is not discussed.
CEO Snehal Patel commented, “This new immune response data further supports the combination of HLA-A*02 and non-HLA-A*02 patients in the same randomized arms. In the US, the FDA recently reviewed such protocol changes and the many non-HLA-A*02 patients on waiting lists that were previously screened are now being enrolled. The screen rate continues to be encouraging, reflecting the high patient interest in the study as we have now screened over 1,300 patients. The Company will have the option to pursue approval for both HLA-A*02 and non-HLA-A*02 patients together using the increased statistical power of a combined analysis of the two patient groups or to pursue subgroups based on planned multiple interim analyses.”
The abstract from today’s immune response data and the members of the Steering Committee follow:
Abstract Number: CT138 – Poster Section 52 on April 20, 2026, 2-5pm PT
Abstract Title: Preliminary delayed-type-hypersensitivity immune response results from open-label arm of on-going Phase III study to evaluate the efficacy and safety of GLSI-100 (GP2 + GM-CSF) in breast cancer patients with residual disease or high-risk PCR after both neo-adjuvant and postoperative adjuvant anti-HER2 therapy, Flamingo-01
Snehal S. Patel1, Jaye Thompson1, F. Joseph Daugherty1, Francois-Clement Bidard2, William J. Gradishar3, Marcus Schmidt4, Miguel Martin5, Joyce A. O’Shaughnessy6, Hope S. Rugo7, Cesar A. Santa-Maria8, Laura M. Spring9, Mothaffar F. Rimawi10
1Greenwich LifeSciences, Stafford, TX,2Institut Curie, Paris, France,3Northwestern University, Chicago, IL,4University Medical Center Mainz, Mainz, Germany,5GEICAM, Madrid, Spain,6Sarah Cannon Research Institute, Dallas, TX,7City of Hope Comprehensive Cancer Center, Duarte, CA,8Johns Hopkins University, Baltimore, MD,9Massachusetts General Hospital, Boston, MA,10Lester and Sue Smith Breast Center, Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX
Background: This Phase III trial is a prospective, randomized, double-blinded, multi-center study (NCT05232916) in HLA-A*02 patients at approximately 140 sites in the US and Europe. A third non-randomized arm of approximately 250 non-HLA-A*02 patients is now fully enrolled and preliminary immune response data is presented below. GP2 is a biologic nine amino acid peptide of the HER2/neu protein delivered in combination with Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) that stimulates an immune response targeting HER2/neu expressing cancers, the combination known as GLSI-100.
Methods: After standard of care neoadjuvant and adjuvant therapy, 6 intradermal injections of GLSI-100 will be administered over the first 6 months and 5 subsequent boosters will be administered over the next 2.5 years. The participant duration of the trial will be 3 years treatment plus 1 additional year follow-up. Immune responses to GP2 were measured over time using delayed-type-hypersensitivity (DTH) skin tests and injection site reactions (ISRs). The patient population is defined by these key eligibility criteria: 1) HER2/neu positive and HLA, 2) Residual disease or High risk pCR (Stage III at presentation) post neo-adjuvant therapy, 3) Exclude Stage IV, and 4) Completed at least 90% of planned trastuzumab-based therapy.
Results: All patients (n=247) were vaccinated with GLSI-100 and continue in treatment and follow-up. A DTH reaction (redness) was used to assess in vivo immune responses in patients. The DTH orthogonal mean was measured 48-72 hours after injection. In this preliminary data analysis, there was a significant increase in percentage of subjects experiencing a DTH reaction in month 4 or month 6 compared to baseline. The frequency of DTH reactions increased by approximately 4x from 5.2% of the patients experiencing a DTH reaction at baseline, prior to any GLSI-100 administration, to 20.4% of the patients experiencing a DTH reaction in month 4 or month 6 (McNemar, p < 0.001). The study is ongoing and data collection and cleaning continue so final results may vary.
Conclusions: The increase in the incidence of DTH reactions over time found in this preliminary analysis of GLSI-100 treated non-HLA-A*02 patients shows that GLSI-100 treatment should not be limited to the HLA-A*02 genotype. Subjects treated with GLSI-100 were increasingly able to mount an immune response to GP2 as evidenced in this preliminary data. Future investigations may explore the use of immune responses to assess: correlation of DTH to ISRs, immunogenicity of GLSI-100 by specific HLA type, timing of boosters to sustain immunity, clinical site performance, and the discontinuation of treatment for non-responders.
The Steering Committee authoring abstract CT138 is comprised of the following experts in the field of breast cancer oncology representing prominent teaching hospitals in the US and 4 of the largest breast oncology networks in the US, Germany, France, and Spain:
Dr. Mothaffar F. Rimawi – Professor of Medicine at the Baylor College of Medicine and Executive Medical Director and Co-Leader, Breast Cancer Program of the Dan L Duncan Comprehensive Cancer Center
Dr. Francois-Clement Bidard – Professor of Medical Oncology, UVSQ/Paris Saclay University, Head of Breast Cancer Group, Institut Curie, Vice-Chair of the French Breast Cancer research group UCBG (Unicancer)
Dr. William J. Gradishar – Professor of Medicine at the Feinberg School of Medicine at Northwestern University, Chief of Hematology and Oncology in the Department of Medicine, and Betsy Bramsen Professor of Breast Oncology
Dr. Sibylle Loibl – Professor (apl) Goethe University Frankfurt/M, Clinical Consultant Centre for Haematology and Oncology/Bethanien Frankfurt/M, CEO of GBG Forschungs GmbH & Chair of the German Breast Group (GBG)
Dr. Miguel Martin – Professor of Medicine, Head, Medical Oncology Service, Gregorio Marañón General University Hospital, Complutense University, Madrid, CEO of GEICAM
Dr. Joyce A. O’Shaughnessy – Celebrating Women Chair in Breast Cancer, Baylor University Medical Center and Chair, Breast Cancer Program, Texas Oncology, US Oncology, Dallas, Texas
Dr. Hope S. Rugo – Director, Women’s Cancers Program, Division Chief, Breast Medical Oncology, Professor, Department of Medical Oncology & Therapeutics Research, City of Hope Comprehensive Cancer Center, Professor Emeritus, University of California, San Francisco
Dr. Cesar A. Santa-Maria – Associate Professor of Oncology, Breast and Gynecological Malignancies Group, Director of Breast Cancer Trials, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
Dr. Laura M. Spring – Assistant Professor, Medicine, Harvard Medical School, Attending Physician, Medical Oncology, Massachusetts General Hospital
About the AACR Annual Meeting 2026
The AACR is the first and largest cancer research organization dedicated to accelerating the conquest of cancer and has more than 61,000 members residing in 143 countries and territories. The AACR Annual Meeting is the focal point of the cancer research community, where scientists, clinicians, other health care professionals, survivors, patients, and advocates gather to share the latest advances in cancer science and medicine. From population science and prevention; to cancer biology, translational, and clinical studies; to survivorship and advocacy; the AACR Annual Meeting highlights the work of the best minds in cancer research from institutions all over the world.
About FLAMINGO-01 Open Label Phase III Data More than 1,000 patients have been screened with a current screen rate of approximately 800 patients per year. The 250 patient non-HLA-A*02 arm is now fully enrolled, where all patients received GLSI-100, which is 5 times more treated patients and recurrence rate data than the approximately 50 patients treated in the Phase IIb trial. The Primary Immunization Series (PIS), which includes the first 6 GLSI-100 injections over the first 6 months and is required to reach peak protection, is followed by 5 booster injections given every 6 months to prolong the immune response, thereby providing longer-term protection.
In the non-HLA-A*02 arm, a preliminary analysis of recurrence rates after the PIS is completed shows an approximately 70-80% reduction in recurrence rate.
This observation is trending similarly to the Phase IIb trial results and hazard ratio where HLA-A*02 patients were treated and where breast cancer recurrences were reduced up to 80% compared to a 20-50% reduction in recurrence rate by other approved products.
The immune response at baseline prior to any GLSI-100 treatment, the increasing immune response during the PIS, and the safety profile of non-HLA-A*02 patients is trending similarly to the HLA-A*02 arms of FLAMINGO-01 and to the Phase IIb study.
Analysis of the open label data from FLAMINGO-01 has been conducted in a manner that maintains the study blind. The open label recurrence rate, immune response, and safety data is based on the patients enrolled to date in FLAMINGO-01 and the data provided by the clinical sites so far, which is not completed or fully reviewed, and is thus preliminary. While comparing any preliminary FLAMINGO-01 data to the Phase IIb clinical trial data may be possible, these preliminary results are not a prediction of future results, and the results at the end of the study may differ.
About GLSI-100 Phase IIb Study
In the prospective, randomized, single-blinded, placebo-controlled, multi-center (16 sites led by MD Anderson Cancer Center) Phase IIb clinical trial of HLA-A*02 breast cancer patients, 46 HER2/neu 3+ over-expressor patients were treated with GLSI-100, and 50 placebo patients were treated with GM-CSF alone. After 5 years of follow-up, there was an 80% or greater reduction in cancer recurrences in the HER2/neu 3+ patients who were treated with GLSI-100, followed, and remained disease free over the first 6 months, which we believe is the time required to reach peak immunity and thus maximum efficacy and protection. The Phase IIb results can be summarized as follows:
80% or greater reduction in metastatic breast cancer recurrence rate over 5 years of follow-up with a peak immune response at 6 months and well-tolerated safety profile.
The PIS elicited a potent immune response as measured by local skin tests and immunological assays.
About FLAMINGO-01 and GLSI-100
FLAMINGO-01 (NCT05232916) is a Phase III clinical trial designed to evaluate the safety and efficacy of Fast Track designated GLSI-100 (GP2 + GM-CSF) in HER2 positive breast cancer patients who had residual disease or high-risk pathologic complete response at surgery and who have completed both neoadjuvant and postoperative adjuvant trastuzumab based treatment. The trial is led by Baylor College of Medicine and currently includes US and European clinical sites from university-based hospitals and academic and cooperative networks with plans to open up to 150 sites globally. In the double-blinded arms of the Phase III trial, approximately 500 HLA-A*02 patients are planned to be randomized to GLSI-100 or placebo, and up to 250 patients of other HLA types are planned to be treated with GLSI-100 in a third arm. The trial has been designed to detect a hazard ratio of 0.3 in invasive breast cancer-free survival, where 28 events will be required. An interim analysis for superiority and futility will be conducted when at least half of those events, 14, have occurred. This sample size provides 80% power if the annual rate of events in placebo-treated subjects is 2.4% or greater.
For more information on FLAMINGO-01, please visit the Company’s website here and clinicaltrials.gov here. Contact information and an interactive map of the majority of participating clinical sites can be viewed under the “Contacts and Locations” section. Please note that the interactive map is not viewable on mobile screens. Related questions and participation interest can be emailed to: [email protected]
About Breast Cancer and HER2/neu Positivity
One in eight U.S. women will develop invasive breast cancer over her lifetime, with approximately 300,000 new breast cancer patients and 4 million breast cancer survivors. HER2 (human epidermal growth factor receptor 2) protein is a cell surface receptor protein that is expressed in a variety of common cancers, including in 75% of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels.
About Greenwich LifeSciences, Inc.
Greenwich LifeSciences is a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery. GP2 is a 9 amino acid transmembrane peptide of the HER2 protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in 75% of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels. Greenwich LifeSciences has commenced a Phase III clinical trial, FLAMINGO-01. For more information on Greenwich LifeSciences, please visit the Company’s website at www.greenwichlifesciences.com and follow the Company’s Twitter at https://twitter.com/GreenwichLS.
Forward-Looking Statement Disclaimer
Statements in this press release contain “forward-looking statements” that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “aim,” “should,” “will,” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on Greenwich LifeSciences Inc.’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict, including statements regarding the intended use of net proceeds from the public offering; consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully in the section entitled “Risk Factors” in Greenwich LifeSciences’ Annual Report on the most recent Form 10-K for the year ended December 31, 2024, and other periodic reports filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date, and Greenwich LifeSciences, Inc. undertakes no duty to update such information except as required under applicable law.
Mark Reichman, Managing Director, Equity Research Analyst, Natural Resources, Noble Capital Markets, Inc.
Refer to the full report for the price target, fundamental analysis, and rating.
Strong Metallurgical Progress. Resolution has advanced metallurgical work at its Antimony Ridge project in Idaho, successfully producing a high-purity antimony trioxide intermediate (99.38% Sb2O3) from stibnite using conventional pyrometallurgical processing. Test work across pyrometallurgy, hydrometallurgy, and ore concentration continues to advance, with further results expected in the near term. The project is supported by high-grade antimony mineralization, consistently exceeding 30% and reaching up to 50%, underscoring its development potential as a domestic source of critical minerals.
Strategic U.S. Processing Opportunity. Resolution is also advancing a strategic plan to establish a U.S.-based antimony processing hub in Idaho, addressing the current lack of modern domestic processing capacity. By leveraging existing infrastructure at the Johnson Creek Mill site, Resolution aims to fast-track development of an integrated “mine-to-product” solution, strengthening supply chains for critical minerals essential to U.S. defense and industrial sectors.
Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.
This Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).
*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.
Mark Reichman, Managing Director, Equity Research Analyst, Natural Resources, Noble Capital Markets, Inc.
Refer to the full report for the price target, fundamental analysis, and rating.
Time charter contract extension. Euroseas Ltd. executed a time charter contract extension for the EM Kea at a gross daily rate of $30,000 for a minimum period of 36 months to a maximum of 38 months, at the charterer’s option. The EM Kea is a 2007-built 3,100 twenty-foot equivalent unit (TEU) feeder container ship. The new charter will commence on July 14, 2026, in direct continuation of its present charter. The charter underscores the shortage of prompt tonnage, which, along with macroeconomic disruptions and uncertainty caused by the war in the Middle East, continues to sustain the firmness of the containership market.
Higher rate and improved charter coverage. The new time charter is an improvement over the previous contract rate of $19,000 per day and is expected to contribute EBITDA of $22.5 million during the minimum contracted period. The new time charter enhances charter coverage for 2025, 2026, and 2027 to approximately 91%, 76%, and 44%, respectively.
Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.
This Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).
*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.
Noble Capital Markets Research Report Monday, April 20, 2026
Companies contained in today’s report:
Euroseas (ESEA)/OUTPERFORM – Updating Estimates to Reflect EM KEA Time Charter Extension Resolution Minerals Ltd (RLMLF)/OUTPERFORM – Progress on Multiple Fronts
Euroseas (ESEA/$72.18 | Price Target: $90) Mark Reichman [email protected] | (561) 999-2272 Updating Estimates to Reflect EM KEA Time Charter Extension Rating: OUTPERFORM
Time charter contract extension. Euroseas Ltd. executed a time charter contract extension for the EM Kea at a gross daily rate of $30,000 for a minimum period of 36 months to a maximum of 38 months, at the charterer’s option. The EM Kea is a 2007-built 3,100 twenty-foot equivalent unit (TEU) feeder container ship. The new charter will commence on July 14, 2026, in direct continuation of its present charter. The charter underscores the shortage of prompt tonnage, which, along with macroeconomic disruptions and uncertainty caused by the war in the Middle East, continues to sustain the firmness of the containership market.
Higher rate and improved charter coverage. The new time charter is an improvement over the previous contract rate of $19,000 per day and is expected to contribute EBITDA of $22.5 million during the minimum contracted period. The new time charter enhances charter coverage for 2025, 2026, and 2027 to approximately 91%, 76%, and 44%, respectively.
Strong Metallurgical Progress. Resolution has advanced metallurgical work at its Antimony Ridge project in Idaho, successfully producing a high-purity antimony trioxide intermediate (99.38% Sb2O3) from stibnite using conventional pyrometallurgical processing. Test work across pyrometallurgy, hydrometallurgy, and ore concentration continues to advance, with further results expected in the near term. The project is supported by high-grade antimony mineralization, consistently exceeding 30% and reaching up to 50%, underscoring its development potential as a domestic source of critical minerals.
Strategic U.S. Processing Opportunity. Resolution is also advancing a strategic plan to establish a U.S.-based antimony processing hub in Idaho, addressing the current lack of modern domestic processing capacity. By leveraging existing infrastructure at the Johnson Creek Mill site, Resolution aims to fast-track development of an integrated “mine-to-product” solution, strengthening supply chains for critical minerals essential to U.S. defense and industrial sectors.
Noble Capital Markets Research Report Thursday, April 16, 2026
Companies contained in today’s report:
CoreCivic, Inc. (CXW)/OUTPERFORM – Additional Flexibility Graham (GHM)/MARKET PERFORM – Accounts Advised by T. Rowe Price to Invest $50 Million in Graham Power Metallic Mines Inc. (PNPNF)/OUTPERFORM – Lion Zone Momentum Builds Vince Holding Corp. (VNCE)/OUTPERFORM – Operating Execution Driving EBITDA Upside
CoreCivic, Inc. (CXW/$20.08 | Price Target: $28) Joe Gomes [email protected] | 561-999-2262 Additional Flexibility Rating: OUTPERFORM
Incremental Term Loan. CoreCivic obtained an incremental term loan in the amount of $100 million from existing lenders under its credit facility. The Company expects to use the $100 million to pay down a portion of the amounts outstanding under its revolver and for working capital and general corporate purposes. With the DHS funding issues, we suspect the federal government has been slow in payment, likely resulting in elevated A/R for CoreCivic.
Updated Debt Details. Following the transaction, CoreCivic’s Amended Credit Facility is in the aggregate principal amount of $800 million, consisting of a $125 million initial term loan, the incremental term loan, and a $575 million revolving credit facility, which has a $25 million sublimit for swingline loans and a $100 million sublimit for the issuance of standby letters of credit.
Graham (GHM/$91.97) Joe Gomes [email protected] | 561-999-2262 Accounts Advised by T. Rowe Price to Invest $50 Million in Graham Rating: MARKET PERFORM
Investment. Yesterday, Graham announced the sale of $50 million of GHM common stock to certain accounts advised by T. Rowe Price Investment Management, Inc. Graham intends to use proceeds from the stock sale to further strengthen the Company’s balance sheet and financial flexibility through debt repayment and help fund future investment in organic and inorganic growth opportunities.
Details. The T. Rowe Price accounts will acquire 599,808 shares, approximately 5% of the outstanding common, of Graham common stock at $83.36 per share, based upon the 20-day average closing price of the company’s common stock on the New York Stock Exchange on April 13, 2026. The transaction is expected to close on April 16, 2026. The T. Rowe accounts will become the fourth largest shareholder following completion of the transaction. The shares will be registered for resale on a registration statement to be filed with the Securities and Exchange Commission within 30 days.
Power Metallic Mines Inc. (PNPNF/$0.84 | Price Target: $2.65) Mark Reichman [email protected] | (561) 999-2272 Lion Zone Momentum Builds Rating: OUTPERFORM
Continued drilling success in the Lion Zone. Recent Winter 2026 drill results further defined the high-grade Lion Zone ahead of a planned 2026 Mineral Resource Estimate (MRE) for the Nisk project that will incorporate Lion Zone mineralization. Infill drilling confirmed continuity of mineralization, highlighted by notable intercepts, including 4.76 meters grading 10.43% copper equivalent (CuEq) and 4.35 meters at 5.94% CuEq, along with broad intervals including 27.1 meters at 2.17% CuEq. These results reinforce confidence in the geological model and support potential resources in the Indicated category.
Near-surface drilling reinforces development potential. Shallow drilling continues to demonstrate strong near-surface mineralization that may be suitable for open-pit extraction, enhancing the project’s development potential. Additional noteworthy results, including 3.10 meters at 5.38% CuEq, further validate the presence of consistent high-grade zones that could underpin future economic studies, including a preliminary economic assessment (PEA).
Strong Q4 caps solid year. Vince delivered Q4 revenue growth of 4.7% to $83.7 million, with DTC up over 10%, and profitability exceeding the high end of guidance despite a ~$2M Saks-related headwind. Adj. EBITDA exceeded our expectations at $4.5 million versus our $2.0 million estimate. This performance underscores the company’s ability to execute effectively even amid wholesale channel disruption and macro uncertainty.
DTC strength and pricing power drive results. Growth was fueled by robust full-price demand, improved customer experience, and successful pricing actions that offset tariff and freight pressures while maintaining unit volumes. Importantly, this signals a structurally higher-quality revenue base with less reliance on promotions.
Noble Capital Markets Research Report Wednesday, April 15, 2026
Companies contained in today’s report:
Commercial Vehicle Group (CVGI)/OUTPERFORM – Sale/Leaseback; Continuing Positive Class 8 Orders NN (NNBR)/OUTPERFORM – Preliminary Q1 2026 Net Sales Expected to Exceed Annual Guidance Run-rate SKYX Platforms (SKYX)/OUTPERFORM – Lands An Important European Hospitality Partnership SPACtrac Report (SPACtrac Report) – Redefining The Future of Sports, Media, and Performance Health
Commercial Vehicle Group (CVGI/$4.09 | Price Target: $6) Joe Gomes [email protected] | 561-999-2262 Sale/Leaseback; Continuing Positive Class 8 Orders Rating: OUTPERFORM
Sale/Leaseback. Commercial Vehicle Group has completed a sale-leaseback transaction for its manufacturing facility in Vonore, Tennessee, which generated $16 million in proceeds. The Company used the net proceeds from the transaction to prepay a portion of its existing term loan facility, thereby reducing the Company’s leverage profile.
Leverage. At the end of 2025, CVG had net debt of $73.1 million, representing a 4.1x net leverage ratio on 2025 adjusted EBITDA. CVG’s near-term focus remains on cash generation and lowering debt levels. Following this transaction, we believe CVG is even better positioned to drive future growth.
NN (NNBR/$1.57 | Price Target: $6) Joe Gomes [email protected] | 561-999-2262 Preliminary Q1 2026 Net Sales Expected to Exceed Annual Guidance Run-rate Rating: OUTPERFORM
Preliminary 1Q26 Revenue. Last night, NN announced that its preliminary Q1 2026 net sales results are expected to demonstrate growth versus the prior year and the Company’s forecast. The Company is maintaining its guidance range on net sales, expecting results to come in toward the top half of its original guidance range of $445 to $465 million.
Positive Momentum on New Business Too. Notably, the New Business program also delivered strong results in Q1. The Company was awarded approximately $43 million of new awards at peak annual sales, centered on the Electric Grid and Data Center markets. With the strength of NN’s new business wins in Q1 and a strong start in Q2, the Company is raising its full-year guidance range, now expecting new business wins to fall within the range of $80 to $90 million in 2026, up from a prior $70 to $80 million range.
SKYX Platforms (SKYX/$1.17 | Price Target: $5) Michael Kupinski [email protected] | (561) 994-5734 Lands An Important European Hospitality Partnership Rating: OUTPERFORM
SKYX Secures Strategic European Partnership with Group OTT. SKYX announced a strategic agreement with European developer Jean-François Ott, founder of Group OTT, to deploy its technologies across hotels and buildings. The partnership designates SKYX’s smart ceiling platform as a brand standard across both new and existing assets. This marks a significant step in positioning SKYX as a core infrastructure provider rather than a product vendor.
Agreement Targets Deployment Across 250+ Projects in the Pipeline, Marking a Key Step Toward International Expansion and Platform Standardization. Group OTT brings a track record of over 250 completed projects valued at more than $4 billion across Europe. The agreement enables potential integration of SKYX technologies across a broad pipeline of hospitality, residential, and commercial developments. This provides SKYX with a scalable entry point into the European market and strengthens its standardization thesis.
SPACtrac Report Michael Kupinski [email protected] | (561) 994-5734 Jacob Mutchler [email protected] | Redefining The Future of Sports, Media, and Performance Health
A new level of competition. Enhanced Group Inc. is an emerging sports, media, and consumer health company seeking to go public via a SPAC merger with A Paradise Acquisition Corp. (APAD). The company is pioneering the “Enhanced Games,” a new athletic competition model that allows medically supervised performance enhancement, while simultaneously building a direct-to-consumer health platform. Its integrated ecosystem combines live events, clinical research, and subscription-based wellness products.
Large market opportunity. Enhanced operates across several high-growth sectors, including telehealth, personalized nutrition, and live sports media, all of which are undergoing structural transformation. Telehealth and performance optimization markets are expanding rapidly due to consumer demand for convenience and personalization, while live sports remain one of the most valuable forms of real-time content globally. These converging trends create a favorable backdrop for new, digitally native platforms that can capture attention and monetize engagement.
Noble Capital Markets Research Report Tuesday, April 14, 2026
Companies contained in today’s report:
First Phosphate Corp. (FRSPF)/OUTPERFORM – First Phosphate Achieves Another Major Milestone Snail (SNAL)/OUTPERFORM – Licensing Agreement Raises Cash Flow; Raise Price Target The Oncology Institute, Inc. (TOI)/OUTPERFORM – CMS Model Shows Medicare Cost Savings, Supporting Our Investment Thesis
First Phosphate Corp. (FRSPF/$0.85 | Price Target: $1.65) Mark Reichman [email protected] | (561) 999-2272 First Phosphate Achieves Another Major Milestone Rating: OUTPERFORM
Advancing financing efforts with international support. First Phosphate has secured a letter of interest (LOI) from the Export and Investment Fund of Denmark (EIFO) for up to €170 million to support equipment and service purchases for its Begin-Lamarche igneous phosphate project in Saguenay–Lac-Saint-Jean, Quebec. EIFO, owned and backed by the Danish government and effectively AAA-rated, would provide a guarantee to participating banks, with its involvement expected to be pro rata and pari passu alongside other senior lenders.
Global experience in export and project finance. EIFO brings extensive global experience in export and project finance, having supported numerous international transactions. The proposed guarantee remains subject to EIFO’s internal credit approvals and completion of project due diligence. The LOI is non-binding pending finalization of borrower, guarantor, and security arrangements, and will be governed by Danish law.
Snail Renegotiates ARK License. The amendment lowers fixed licensing costs from $2.0 million to $1.5 million per month, implying $1.5 million in quarterly savings. The obligation remains in place until the release of ARK 2, preserving near-term cost visibility. The move shows that the company is independently evaluating contracts on a timely basis.
DLC Payment Terms Revised to Reduce Future Cash Obligations. The amendment replaces blanket $5 million DLC payments with a more selective structure, excluding certain content such as DLCs already bundled in ARK: Survival Ascended. This change further moderates future cash outflows tied to the franchise. Improved cash flow generation provides greater flexibility to invest in upcoming titles and franchise development. It also reduces financial risk as the company transitions toward the next major ARK release.
The Oncology Institute, Inc. (TOI/$3.3 | Price Target: $8) Robert LeBoyer [email protected] | (212) 896-4625 CMS Model Shows Medicare Cost Savings, Supporting Our Investment Thesis Rating: OUTPERFORM
TOI Methodology Continues To Improve Medicare Cost Savings. TOI announced new data from the Enhancing Oncology Model (EOM) developed by the Centers for Medicare & Medicaid Services (CMS). Data from CMS shows that during Performance Period 3, the six-month period beginning July 2024, TOI achieved cost savings of $1.8 million, equating to $6,400 per patient-episode. This compares with the Performance Period 2, from January 2024 to June 2024, in which savings were $1.1 million or $3,500 per episode.
TOI Methodology Fits Well With The EOM. The CMS Innovation Center developed the EOM as a total-cost-of-care model to improve cancer care for Medicare Fee-for-Service beneficiaries. It incentivizes oncology practices to deliver coordinated care for patients receiving chemotherapy. The EOM model has identified pharmacy, avoidable acute care, and supportive care as the three main areas for cost reduction and quality-of-care improvements.
Noble Capital Markets Research Report Friday, April 10, 2026
Companies contained in today’s report:
Resolution Minerals Ltd (RLMLF)/OUTPERFORM – Antimony Ridge Takes a Big Step Forward Resources Connection (RGP)/OUTPERFORM – 3Q26 Results In-Line, But End Markets Remain Challenging Vince Holding Corp. (VNCE)/OUTPERFORM – Margins Trending Towards the High End of Guidance
Resolution Minerals Ltd (RLMLF/$0.04 | Price Target: $0.15) Mark Reichman [email protected] | (561) 999-2272 Antimony Ridge Takes a Big Step Forward Rating: OUTPERFORM
Fast-41 Designation. Resolution Minerals Ltd (OTCQB: RLMLF, ASX: RML) is advancing its Antimony Ridge Project in Idaho as a strategically significant source of antimony within the United States, reinforced by its recent inclusion in the Federal FAST 41 Permitting Transparency Program. This designation underscores the project’s importance to national security and critical mineral supply chains while supporting accelerated permitting, enhanced regulatory coordination, and increased visibility with investors and strategic partners.
Large-Scale Potential. The project demonstrates strong large-scale potential, with recent modeling defining an extensive and expanding mineralized system hosting high grade antimony and silver across a substantial footprint. Historical production and recent sampling confirm exceptionally high grades, while mineralization remains open in multiple directions, indicating considerable upside and resource growth potential.
Resources Connection (RGP/$3.46 | Price Target: $6) Joe Gomes [email protected] | 561-999-2262 3Q26 Results In-Line, But End Markets Remain Challenging Rating: OUTPERFORM
Overview. For the third quarter of fiscal 2026, Resources Connection produced results that were aligned with management’s previous guidance for revenue and gross margin, while run-rate SG&A expenses were better than the outlook. During the quarter, management continued to strengthen leadership, meaningfully reduced the cost structure, took steps to simplify the business portfolio, and began reinvesting selectively to support future growth.
3Q26 Results. Revenue in 3Q26 was $107.9 million compared to $129.4 million in 3Q25. We were at $108 million. On a same-day constant currency basis, revenue decreased by $25.4 million, or 19.6%. Billable hours decreased 16.3% year-over-year, and the Company average bill rate for 3Q26 decreased 1.0% year-over-year, or 2.1% on a constant currency basis. RGP reported a GAAP net loss of $9.5 million, or a loss of $0.28/sh. Adjusted net loss was $0.09/sh. We were at a loss of $0.31/sh and $0.08/sh, respectively.
Vince Holding Corp. (VNCE/$2.45 | Price Target: $5.5) Michael Kupinski [email protected] | (561) 994-5734 Jacob Mutchler [email protected] | Margins Trending Towards the High End of Guidance Rating: OUTPERFORM
Solid holiday performance. For the nine-week period ended January 3, 2026, total company net sales increased 5.3% year over year, supported primarily by steady demand and continued strength in the Direct-to-Consumer segment. Furthermore, management attributed the improvement to ongoing investments in customer experience, digital capabilities, and omnichannel engagement.
DTC leads the way. Notably, Direct-to-Consumer revenue increased 9.7% versus the prior-year holiday period, underscoring strong traffic conversion across e-commerce and retail locations. In contrast, the Wholesale segment declined 2.7% year over year, reflecting disruption in receipt flow related to its partner Saks Global. Despite this pressure, management indicated that strong point-of-sale performance with key partners partially offset the disruption.
Noble Capital Markets Research Report Thursday, April 9, 2026
Companies contained in today’s report:
AZZ (AZZ)/OUTPERFORM – AZZ To Report FY 2026 Financial Results on April 22 QuoteMedia Inc. (QMCI)/OUTPERFORM – Entering a Multi-Year Growth Phase Xcel Brands (XELB)/OUTPERFORM – A Solid Foundation For Growth
AZZ (AZZ/$133.47 | Price Target: $160) Mark Reichman [email protected] | (561) 999-2272 AZZ To Report FY 2026 Financial Results on April 22 Rating: OUTPERFORM
FY 2026 financial results. AZZ will release fourth quarter and FY 2026 financial results after the market close on Wednesday, April 22. Management will host an investor conference call and webcast on Thursday, April 23, at 11:00 am ET. We anticipate the company will elaborate on its FY 2027 corporate guidance and capital allocation priorities, along with discussing the market outlook and strategic drivers for each of its business segments.
Corporate guidance. FY 2026 sales, EBITDA, and EPS are expected to be in the range of $1.625 to $1.725 billion, $360 to $380 million, and $5.90 to $6.20, respectively. FY 2027 sales are expected to be in the range of $1.725 to $1.775 billion, adjusted EBITDA is expected to be in the range of $360.0 to $400.0 million, and adjusted diluted EPS is expected to be in the range of $6.50 to $7.00.
QuoteMedia Inc. (QMCI/$0.15 | Price Target: $0.23) Michael Kupinski [email protected] | (561) 994-5734 Entering a Multi-Year Growth Phase Rating: OUTPERFORM
Q4 exceeds revenue expectations. QuoteMedia reported Q4 revenue of $5.35M (+14% y/y) and FY2025 revenue of $20.3M (+8% y/y), reflecting solid top-line momentum, while profitability declined with Adjusted EBITDA of $1.0M (vs. $1.8M prior year) and a net loss of $2.3M, driven by investment and accounting treatment of development costs.
Revenue Drivers & Earnings Dynamics. Growth was led by Corporate Quotestream (enterprise), benefiting from larger contracts, higher ARPC, and cross-selling of data and SaaS solutions, while earnings were pressured by higher expensing of development costs (vs. capitalization), which impacted reported profitability but not cash flow.
Xcel Brands (XELB/$1.53 | Price Target: $5) Michael Kupinski [email protected] | (561) 994-5734 Jacob Mutchler [email protected] | A Solid Foundation For Growth Rating: OUTPERFORM
Q4 Results. The company reported Q4 revenue of $1.2 million and an adj. EBITDA loss of $0.6 million, both of which were modestly lower than our estimates of $1.7 million and a loss of $0.5 million, respectively, as illustrated in Figure #1 Q4 Results. Notably, we view 2025 as a transformational year for the company, given several key partnerships and a more efficient operating structure that positions the company for growth.
Favorable Release Pipeline. In 2026, the company is expected to enter a more significant phase of its growth strategy, centered on brand launches and portfolio expansion. Cesar Millan, Gemma Stafford, and Jenny Martinez are expected to debut on QVC and HSN in Q2, with distribution expanding to brick-and-mortar retail and Amazon in the back half of the year. Additionally, Coco Rocha is expected to launch later in 2026.
Noble Capital Markets Research Report Wednesday, April 8, 2026
Companies contained in today’s report:
Direct Digital Holdings (DRCT)/MARKET PERFORM – Early Signs of Stabilization Emerge GeoVax Labs (GOVX)/OUTPERFORM – GeoVax Presents Data On New Single-Dose Mpox Vaccine Greenwich LifeSciences, Inc. (GLSI)/OUTPERFORM – New Claims Filed To Expand Patent Estate Covering GP2 QuoteMedia Inc. (QMCI)/OUTPERFORM – Revenue Momentum Picks Up Xcel Brands (XELB)/OUTPERFORM – Solid Foundation For Growth In 2026
Direct Digital Holdings (DRCT/$0.78) Michael Kupinski [email protected] | (561) 994-5734 Jacob Mutchler [email protected] | Early Signs of Stabilization Emerge Rating: MARKET PERFORM
Post Q4 investor call. This report provides additional color on the recently reported fourth-quarter and full-year 2025 results and the outlook for 2026 and beyond. We are posting 2027 estimates, which anticipate mid-teen revenue growth and positive adj. EBITDA.
New customer wins in energy and expanding vertical mix improve growth quality and reduce seasonality. Buy-side momentum was driven by new customer additions, particularly in the energy vertical and by expansion into education. This diversification is helping stabilize revenue trends and reduce historical second-half weakness.
GeoVax Labs (GOVX/$1.21 | Price Target: $10) Robert LeBoyer [email protected] | (212) 896-4625 GeoVax Presents Data On New Single-Dose Mpox Vaccine Rating: OUTPERFORM
Preclinical Study Compared Single-Dose MVA With Two-Dose Standard Vaccine. GeoVax presented preclinical data at the World Vaccine Congress Washington 2026 comparing its current pre-Phase-3 GEO-MVA vaccine for Mpox with its new MVA-X version. The new MVA-X includes a peptide sequence that elicits a strong T-cell response that requires only one dose to achieve protection instead of two.
Immune Checkpoint Modulation Improves The Response. The new MVA-X includes an immunomodulatory peptide designed to improve T-cell responses. The peptide modulates the PD-1 immune checkpoint pathway to block inhibitory signaling to magnify T-cell activation, improve the durability of the T-cell response, and enhance immune memory.
Greenwich LifeSciences, Inc. (GLSI/$22.03 | Price Target: $45) Robert LeBoyer [email protected] | (212) 896-4625 New Claims Filed To Expand Patent Estate Covering GP2 Rating: OUTPERFORM
New Data Added To Expand Patent Claims. Greenwich LifeSciences announced that it has filed new patent claims to expand the patent estate covering GP2, the proprietary compound in GLSI-100. The new claims add recently announced data from the Phase 3 FLAMINGO-01 trial that show the immune response and recurrence rate for non-HLA*02 patients. These claims could expand both the scope and the term of the patent estate beyond previous claims from HLA*02 patients.
Broadening Patent Protection Protects Against Competitors. Patent claims covering the immune response that results from GLSI-100 treatment could help lock out competitors trying to develop similar compounds. If a new compound were able to avoid patents covering GP2, it would be blocked by the new claims covering the immune response that follows.
QuoteMedia Inc. (QMCI/$0.14 | Price Target: $0.23) Michael Kupinski [email protected] | (561) 994-5734 Revenue Momentum Picks Up Rating: OUTPERFORM
Exceeds Q4 revenue expectations. QuoteMedia reported Q4 revenue of $5.35M (+14% y/y) and FY2025 revenue of $20.3M (+8% y/y), reflecting solid top-line momentum. Profitability declined in the full year 2025, with Adjusted EBITDA of $1.0M (vs. $1.8M prior year) and a net loss of $2.3 million, driven by investment and accounting treatment of development costs.
Key growth drivers. Revenue growth was led by Corporate Quotestream (enterprise), benefiting from larger contracts, higher ARPC, and cross-selling of data and SaaS solutions. Interactive Content revenue increased a strong 18.3%, better than our 8% growth estimate. Earnings were pressured by higher expensing of development costs (vs. capitalization), which impacted reported profitability.
Xcel Brands (XELB/$1.46 | Price Target: $7) Michael Kupinski [email protected] | (561) 994-5734 Jacob Mutchler [email protected] | Solid Foundation For Growth In 2026 Rating: OUTPERFORM
Q4 Results. The company reported Q4 revenue of $1.2 million and an adj. EBITDA loss of $0.6 million, both of which were modestly lower than our estimates of $1.7 million and a loss of $0.5 million, respectively, as illustrated in Figure #1 Q4 Results. Notably, we view 2025 as a transformational year for the company, driven by several key partnerships that position it on a solid foundation for growth in 2026 and beyond.
Strategic partnerships. The company’s influencer brands, with Jenny Martinez, Gemma Stafford, Cesar Millan, and Coco Rocha, are expected to launch throughout 2026. Notably, these partnerships have driven the company’s social media following from 5 million at the start of 2025 to approximately 46 million today. In our view, the company is well-positioned to reach its goal of 100 million social media followers in 2026.
Noble Capital Markets Research Report Tuesday, April 7, 2026
Companies contained in today’s report:
Century Lithium Corp. (CYDVF)/OUTPERFORM – Moving to the Next Phase of Development Newsmax (NMAX)/OUTPERFORM – Structural Growth Story Intact; Tweaking Price Target
Century Lithium Corp. (CYDVF/$0.27 | Price Target: $3.05) Mark Reichman [email protected] | (561) 999-2272 Moving to the Next Phase of Development Rating: OUTPERFORM
Updated feasibility study. Century recently filed its updated 2026 NI 43-101 feasibility study for its 100%-owned Angel Island Lithium Project in Nevada. The updated study reflects engineering optimization and improvements that materially strengthen the project’s economic profile and highlight Angel Island as one of the most significant and economically robust sedimentary lithium developments in the United States.
Next steps. With the completion and filing of the 2026 Feasibility Study and the recent C$7 million financing, the company is well positioned to advance the Angel Island project to its next development stages. Planned activities include submitting a Plan of Operations to the Bureau of Land Management to initiate the National Environmental Policy Act (NEPA) review process, advancing Nevada state permitting, progressing detailed engineering, and continuing engagement with strategic and downstream partners. Century also intends to further evaluate the rate of earth element recovery at Angel Island and continue discussions with potential offtake and project finance partners.
Newsmax (NMAX/$5.49 | Price Target: $17) Michael Kupinski [email protected] | (561) 994-5734 Jacob Mutchler [email protected] | Structural Growth Story Intact; Tweaking Price Target Rating: OUTPERFORM
Strong Q4 execution with continued top-line momentum. Newsmax delivered Q4 revenue growth of 9.6% year-over-year, driven by affiliate fee expansion and resilient advertising demand, outperforming expectations in a non-election year environment. The company continues to scale across cable, streaming (FAST), subscription, and digital platforms, expanding distribution to 100+ countries and reinforcing its position as the #4 cable news network.
Affiliate fee upside remains key long-term catalyst. Ongoing contract renewals and repricing opportunities provide meaningful upside potential, with current rates still significantly below industry peers. Based on recent contracts and a favorable 2026 outlook, we have revised our 2026 affiliate fee revenue estimate upward from $43.4 million to $49.8 million.
Noble Capital Markets Research Report Monday, April 6, 2026
Companies contained in today’s report:
Cocrystal Pharma (COCP)/OUTPERFORM – CDI-988 Receives Fast Track Designation, Raising Its Profile Nutriband (NTRB)/OUTPERFORM – First Marketing Partnership Expands Territory and Brings A Product Approval Ocugen (OCGN)/OUTPERFORM – Dosing Completed Early In The OCU410ST Phase 2/3 GARDian Trial
Cocrystal Pharma (COCP/$1.51 | Price Target: $10) Robert LeBoyer [email protected] | (212) 896-4625 CDI-988 Receives Fast Track Designation, Raising Its Profile Rating: OUTPERFORM
Cocrystal Receives Fast Track Designation. CDI-988 has been awarded Fast Track Designation by the FDA, a designation given to drugs that treat serious conditions with no effective treatments. It is intended to streamline the clinical development and shorten regulatory review for products treating unmet medical needs. The designation should save Cocrystal time and clinical expenses, as well as give recognition to CDI-988 as a meaningful new vaccine for the prevention and treatment of norovirus.
Fast Track Designation Is Intended To Help Drug Development. The FDA’s Fast Track designation has several benefits to help companies develop drugs for unmet medical needs. During the development process, Cocrystal can have more frequent communications with the FDA to obtain its guidance throughout the process.
Nutriband (NTRB/$3.63 | Price Target: $15) Robert LeBoyer [email protected] | (212) 896-4625 First Marketing Partnership Expands Territory and Brings A Product Approval Rating: OUTPERFORM
Marketing Partnership Covering Costa Rica Brings First Success. In February, Nutriband signed an agreement with Costa Rica’s Innomedica CCB, making it the territory’s exclusive distributor of Nutriband products and AVERSA Fentanyl upon approval. Shortly afterward, the Costa Rican Ministry of Health approved the Nutriband kinesiology tapes for import and sale, making them the first Nutriband products that Innomedica has guided through local regulatory approvals. It plans to begin marketing efforts for the kinesiology tapes, the mosquito repellent patch, and begin AVERSA Fentanyl patch marketing in anticipation of approval.
Moving Forward With AVERSA Fentanyl. Nutriband is preparing to start its clinical trial testing to test the abuse deterrence of its proprietary AVERSA Fentanyl patch. This trial will test a generic fentanyl patch against the AVERSA Fentanyl patch to determine if substance abusers can obtain the drug without activating the with aversive chemicals. We expect the trial to begin around mid-FY2026.
Ocugen (OCGN/$1.79 | Price Target: $12) Robert LeBoyer [email protected] | (212) 896-4625 Dosing Completed Early In The OCU410ST Phase 2/3 GARDian Trial Rating: OUTPERFORM
OCU410ST Treatment Has Been Completed Ahead Of Schedule. The Stargardt disease Phase 2/3 Trial testing OCU410ST has completed patient enrollment and treatment in 9 months, beating our estimated time of 12 months. The trial enrolled 63 patients, with an interim analysis planned when 24 patients have completed the follow-up evaluation at month 8 after treatment. This is expected to be announced in 3Q26. The primary endpoint for the BLA is based on the 1-year evaluation, which should occur around 1Q27.
OCU410ST Restores Pathways To Prevent Blindness. OCU410ST (AAV5-hRORA) uses Ocugen’s proprietary modifier gene technology to deliver hRORA, a gene that controls pathways that can lead to macular degeneration in Stargardt disease. OCU410ST is a single subretinal injection that leads to durable gene expression, restoring homeostasis in those pathways, preventing death of cells in the retina, and preserving visual function.
Updating 1Q 2026 estimates. We have lowered our 1Q and FY 2026 EPU estimates to $(0.02) and $2.20, respectively, from $0.61 and $2.60. We have marked-to-market ARLP’s holding of bitcoins, which amounted to 592 bitcoins as of year-end 2025. The price of bitcoin closed at $87,508.83 on December 31, 2025, compared to $68,233.31 on March 31. We anticipate that the value of digital assets in Q1 2026 could decrease by approximately $11.4 million if all bitcoins were held through the end of the first quarter. Because it would represent a non-cash unrealized loss, it has no impact on our adjusted EBITDA estimate. Moreover, our EPU estimate reflects a non-cash impairment charge of $43 million related to a decision to cease longwall production at the Mettiki Mining complex, although it has no impact on our adjusted EBITDA estimate.
FY 2026 estimates. We have also adjusted the cadence of coal sales throughout the year, with lower volumes in the first quarter, along with higher segment adjusted EBITDA expense per ton. While we have lowered our FY 2026 EPU estimates, our adjusted EBITDA estimate declined only modestly to $708.3 million from $708.4 million due, in part, because our estimates reflect greater tonnage in the second half of the year when adjusted EBITDA expense per ton is lower, and margins are stronger. Quarterly coal sales volume is expected to be lowest in the first quarter, increase modestly in the second, and peak in the back half as longwall move disruptions abate.
Commercial Vehicle Group (CVGI)/$3.52) Joe Gomes [email protected] | (561 )999-2262 A CFO Transition Rating: OUTPERFORM
A Transition. Last night, Commercial Vehicle Group announced that Andy Cheung, Chief Financial Officer, will be resigning from his position effective April 15, 2026, to accept a position as Chief Financial Officer of a mid-cap publicly traded company. Angie O’Leary, currently Corporate Controller and Chief Accounting Officer, has been promoted to Interim Chief Financial Officer and will continue to serve as the Corporate Controller and Chief Accounting Officer. At this time, CVG does not intend to initiate a search process to identify a permanent CFO replacement.
Ms. O’Leary. Ms. O’Leary has served as the Company’s Senior Vice President, Corporate Controller, and Chief Accounting Officer since December 2020. Prior to joining the Company, Ms. O’Leary held several leadership roles at Vertiv Holdings Co. from May 2017 to December 2020, including Interim Corporate Controller. Earlier in her career, Ms. O’Leary held several roles at Deloitte & Touche LLP, beginning in January 2004, culminating in the role of Senior Manager – Audit, from August 2010 to May 2017.
Direct Digital Holdings (DRCT/$0.77) Michael Kupinski [email protected] | (561) 994-5734 Jacob Mutchler [email protected] | Buy-Side Pivot Gains Traction Rating: MARKET PERFORM
An in-line Q4. Direct Digital reported Q4 revenue of $8.4M (down 7% YoY), reflecting a sharp decline in sell-side activity, partially offset by strong buy-side growth (+28% YoY). Total company revenues of $8.4 million were better than our $7.7 million estimate. Q4 adj. EBITDA loss was in line with expectations, at $3.6 million versus $3.4 million.
Buy-side momentum offsetting structural sell-side decline. The primary driver of the quarter was strength in the buy-side segment, supported by improved customer acquisition, higher conversion rates, and increased contribution from returning customers, while the sell-side business experienced significant contraction due to reduced inventory and strategic deprioritization.
Results weaker than expected. Full year 2025 revenue of $361.9 million was well below our $434.2 million estimate. Management emphasized that the Medicare Advantage market remains in a structural reset heading into 2026, with carriers prioritizing retention, member quality, margin integrity, and disciplined unit economics over enrollment growth. Full year 2025 adj. EBITDA loss estimate of $35.1 million was more than our loss estimate of $29.6 million.
Strategic reset. The company has deliberately reduced Medicare Advantage enrollments where first-renewal economics were unattractive, prioritizing long-term profitability and appropriate consumer plan fit. Importantly, the company managed cash flow despite the significant revenue drop, a testament to its structural cost restructuring.
Great Lakes Dredge & Dock (GLDD/$17) Joe Gomes [email protected] | 561-999-2262 Acquisition by Saltchuk Completed Rating: NOT RATED
Acquisition Completed. The acquisition of Great Lakes Dredge & Dock by Saltchuk Resources was completed on April 1st. Announced on February 11th, Saltchuk paid $17/sh for the outstanding GLDD stock, an enterprise value of approximately $1.5 billion.
Tender Offer. As of the expiration of the tender offer, approximately 53,738,558 shares of Great Lakes common stock were validly tendered and not validly withdrawn pursuant to the tender offer, representing approximately 79.88% of the issued and outstanding shares of Great Lakes common stock. As a result of the completion of the transaction, prior to the opening of trading on the NASDAQ on April 1, 2026, all shares of Great Lakes common stock ceased trading, and all shares of Great Lakes common stock will subsequently be delisted from NASDAQ and deregistered under the Securities Exchange Act of 1934.
Private placement financing. Summit Midstream announced a private placement of 1,351,351 shares of its common stock with an affiliate of Tailwater Capital LLC at a price of $31.08 per share to raise $42.0 million. Summit intends to use the net proceeds to reduce borrowings under the company’s asset-based lending credit facility and to fund organic growth capital projects. Following the transaction, Tailwater and its affiliated entities are expected to own ~39% of Summit’s outstanding equity.
Updating estimates and valuation. Following the financing, Summit will have 13.8 million common shares, along with 6.5 million Class B shares outstanding for a total of 20.3 million shares. We have made no changes to our revenue or EBITDA estimates, although the higher share count has a minor impact on per share estimates and lowers our valuation per share to $46.00 from $48.50.
Noble Capital Markets Research Report Wednesday, April 1, 2026
Companies contained in today’s report:
Cadrenal Therapeutics (CVKD)/OUTPERFORM – Cadrenal Reports FY2025 With Clinical Progress First Phosphate Corp. (FRSPF)/OUTPERFORM – Firing on All Cylinders GoHealth (GOCO)/OUTPERFORM – Resetting the Model for Sustainable Growth MAIA Biotechnology (MAIA)/OUTPERFORM – MAIA Reports Two-Year Survival Data At Medical Conference NeuroSense Therapeutics Ltd. (NRSN)/OUTPERFORM – NeuroSense Reports FY2025 With Outlook For The Year
Progress On CAD-1005 Reported With FY2025 Results. Cadrenal reported a loss for 4Q25 of $3.0 million or $(1.42) per share and a FY2025 loss of $13.2 million or $(6.64) per share. Importantly, it recently held its End-Of-Phase 2 meeting with the FDA to receive guidance for the planned Phase 3 trial for CAD-1005 in HIT (heparin-induced thrombocytopenia). The company had cash and equivalents of $4.0 million on December 31, 2025.
Lead Indication Reported Phase 2 Data. As discussed in our Research Note on February 25, Cadrenal reported results from its Phase 2 study of CAD-1005 in HIT. The trial was designed to show CAD-1005 improved platelet recovery and tested platelet count recovery as a biomarker for thrombosis and outcome. The data did not show a correlation between platelet count normalization and thrombotic events, but did show an important reduction in thrombotic events exceeding 25% in the CAD-1005 treatment arm compared with placebo.
First Phosphate Corp. (FRSPF/$0.7 | Price Target: $1.65) Mark Reichman [email protected] | (561) 999-2272 Firing on All Cylinders Rating: OUTPERFORM
Expanded infill drill program. First Phosphate completed an expanded infill drill program, totaling approximately 40,000 meters, that was launched in October at its Begin-Lamarche property in Saguenay-Lac-St. Jean, Quebec. The drilling program, which was expanded from 30,000 meters of drilling, confirmed continuity of phosphate mineralization across the existing resource horizon and discovered two new mineralized intersects in the Northern and Southern zones.
Updated geological model. The incremental 10,000 meters of drilling was designed to better understand the new intersects and test mineralization at depth in areas across the Northern and Southern zones. The company is processing the full set of drill results from its original and expanded drill program with the goal of updating the geological model in the coming weeks.
GoHealth (GOCO/$1.51 | Price Target: $10) Michael Kupinski [email protected] | (561) 994-5734 Jacob Mutchler [email protected] | Resetting the Model for Sustainable Growth Rating: OUTPERFORM
Results weaker than expected. Full year 2025 revenue of $361.9 million was well below our $434.2 million estimate. Management emphasized that the Medicare Advantage market remains in a structural reset heading into 2026, with carriers prioritizing retention, member quality, margin integrity, and disciplined unit economics over enrollment growth. Full year 2025 adj. EBITDA loss estimate of $35.1 million was more than our loss estimate of $29.6 million.
Strategic reset. The company has deliberately reduced Medicare Advantage enrollments where first-renewal economics were unattractive, prioritizing long-term profitability and appropriate consumer plan fit. At the same time, it has maintained leadership in Special Needs Plans (SNP), benefiting from carrier focus on high-need, high-retention populations.
MAIA Biotechnology (MAIA/$1.4 | Price Target: $14) Robert LeBoyer [email protected] | (212) 896-4625 MAIA Reports Two-Year Survival Data At Medical Conference Rating: OUTPERFORM
New Data Presented Shows Long-Term Survival. MAIA presented data from its Phase 2 THIO-101 trial at the European Lung Cancer Congress 2026 (ELCC) held recently in Copenhagen, Denmark. The presentation included data from patients with non-small cell lung cancer (NSCLC) who had relapsed after treatment with standard chemotherapy. Data from 8 patients showed survival exceeding 2 years and greatly exceeded the expected survival for patients at their stage of disease.
Phase 2 Trial Design. THIO-101 was designed in three stages. Part A was basic safety, and Part B was a dose-finding stage. These two stages treated a total of 79 patients. The ongoing Part C is an expansion stage enrolling up to 48 participants in Asia and Europe. The patients are treated with ateganosine (aka THIO) followed by cemiplimab (Libtayo, from Regeneron).
NeuroSense Therapeutics Ltd. (NRSN/$0.76 | Price Target: $9) Robert LeBoyer [email protected] | (212) 896-4625 NeuroSense Reports FY2025 With Outlook For The Year Rating: OUTPERFORM
FY2025 Reported With PrimeC Progress Review. NeuroSense reported a loss for FY2025 of $11.1 million or $(0.44) per share. The company gave updates to its ongoing PrimeC development programs and expected milestones for the coming year in ALS and Alzheimer’s disease. As of December 31, 2025, NeuroSense had cash of approximately $0.2 million.
Phase 3 In ALS Has Received FDA Clearance. During November 2025, NeuroSense received FDA clearance to initiate the Phase 3 trial in ALS. The company has completed commercial-scale manufacturing and continues to prepare for the Phase 3 trial, which we expect to begin later in FY2026.
Noble Capital Markets Research Report Tuesday, March 31, 2026
Companies contained in today’s report:
Unicycive Therapeutics (UNCY)/OUTPERFORM – FY2025 Loss Reported With OLC PDUFA Data Approaching
Unicycive Therapeutics (UNCY/$6.11 | Price Target: $60) Robert LeBoyer [email protected] | (212) 896-4625 FY2025 Loss Reported With OLC PDUFA Data Approaching Rating: OUTPERFORM
NDA Sumisssion Was Accepted In January. Unicycive reported loss for FYQ25 of $26.6 million or $(1.67) per share. Importantly, the resubmission of the NDA for oxylanthanum calcium (OLC), its phosphate binder for controlling high phosphate levels in renal dialysis patients, was accepted for filing by the FDA. The PDUFA data is June 19, 2026. Cash on December 31, 2026 was $54.9 million, which we estimate is sufficient to last through product launch and the first quarter of OLC sales.
We Believe Previous Issues Have Been Settled. The NDA was submitted in December 2025 and accepted for filing in January. FDA acceptance and notification of the PDUFA date signifies that the application is complete for review. There were no questions about the third-party manufacturing issue that stopped the review process in June 2025. We believe the corrective actions have addressed the problem, allowing for marketing approval by June 2026.
Noble Capital Markets Research Report Monday, March 30, 2026
Companies contained in today’s report:
FreightCar America (RAIL)/OUTPERFORM – Updating Estimates; Rating Remains an Outperform
FreightCar America (RAIL/$8.04 | Price Target: $16.5) Mark Reichman [email protected] | (561) 999-2272 Hans Baldau [email protected] | Updating Estimates; Rating Remains an Outperform Rating: OUTPERFORM
Updating estimates. We revised our FY 2026 estimates to reflect lower margins in the first and second quarters. While our full year revenue, EBITDA, and EPS estimates are unchanged, the quarterly allocations have shifted. We forecast first quarter revenue, EBITDA, and EPS of $86.0 million, $7.0 million, and $0.04, respectively, compared to our prior estimates of $89.0 million, $8.8 million, and $0.08. We have assumed growing Aftermarket segment revenue throughout the year. Our FY 2026 revenue, EBITDA, and EPS estimates remain $525.0 million, $44.5 million, and $0.54, respectively.
Lowering 1H’ 2026 expectations. We think the first quarter of 2026 will reflect the fewest deliveries during the year, along with a less favorable product mix. Accordingly, we expect 2026 deliveries, revenue, and earnings to be weighted toward the second half of the year, supported by higher volumes, an improved product mix, and increased contributions from new builds and retrofit programs.
Noble Capital Markets Research Report Friday, March 27, 2026
Companies contained in today’s report:
Newsmax (NMAX)/OUTPERFORM – Among The Few Media Growth Companies SKYX Platforms (SKYX)/OUTPERFORM – Tempered Near-Term Outlook, Long-Term Scaling Remain
Newsmax (NMAX/$5.98 | Price Target: $21) Michael Kupinski [email protected] | (561) 994-5734 Jacob Mutchler [email protected] | Among The Few Media Growth Companies Rating: OUTPERFORM
Exceeds Q4 results. Newsmax delivered solid fourth quarter results with total revenue of $52.2 million, representing a 9.6% year-over-year increase, driven primarily by growth in broadcasting revenue, particularly affiliate fees and linear advertising demand. Importantly, profitability trends improved meaningfully, with adjusted EBITDA outperforming expectations, reflecting early signs of operating leverage despite continued investment in content and infrastructure.
Quarter Highlights: The quarter was characterized by strong execution across key operating metrics, including robust affiliate fee growth (+17.9%), continued resilience in advertising revenue, and significant audience expansion across both linear and streaming platforms.
Q4 results. SKYX reported revenue of $24.9M versus our $26.5M estimate, reflecting a modest miss tied to the delayed rollout of the SKYFAN & Turbo Heater and disruption from its new AI-driven e-commerce platform. Adj. EBITDA loss of $2.7M was worse than our expectation of a loss of $0.4M.
Near-term catalysts. The SKYFAN & Turbo Heater has launched across major retailers, and we expect broader distribution and SKU expansion to support growth through 2026. The new AI-driven platform should improve conversion across the company’s owned websites following near-term disruption.
Noble Capital Markets Research Report Thursday, March 26, 2026
Companies contained in today’s report:
Cardiff Oncology (CRDF)/OUTPERFORM – KOL Discussion Of Onvansertib Supports Our Outperform Rating GeoVax Labs (GOVX)/OUTPERFORM – MVA Vaccine Makes Progress Toward Phase 3 For Mpox Resolution Minerals Ltd (RLMLF)/OUTPERFORM – Idaho’s Next Gold and Critical Minerals District
Cardiff Oncology (CRDF/$1.73 | Price Target: $12) Robert LeBoyer [email protected] | (212) 896-4625 KOL Discussion Of Onvansertib Supports Our Outperform Rating Rating: OUTPERFORM
Cardiff Oncology Held A KOL Discussion. On March 25, Cardiff Oncology held a webcast with two world-renown oncologists with experience in drug development and patient treatment. The discussion began with a review of the Phase 2 data by Dr. Mani Mohindru, the Interim CEO. The discussion centered on aspects of the trial, including the outcome data, practical use, and competitive therapies.
The Discussion Included Significance Of Phase 2 Outcomes. The presentation began with a review of Phase 2 data announced in January 2026, with comments by the KOLs. They pointed to the response rate (RR) of 72.2% and the median progression-free survival (PFS) that has not yet been reached. Importantly, onvansertib did not cause additional toxicities to the combination chemotherapy regimen.
GeoVax Labs (GOVX/$1.5 | Price Target: $10) Robert LeBoyer [email protected] | (212) 896-4625 MVA Vaccine Makes Progress Toward Phase 3 For Mpox Rating: OUTPERFORM
Mpox Vaccine Clinical Supplies Expected To Be Ready Soon. GeoVax announced the completion of clinical supply testing of GEO-MVA, its modified vaccinia ankara (MVA) vaccine for Mpox/smallpox. The release of vaccine that can be used in clinical trials is expected in early April. This is an important milestone in preparation for the Phase 3 trial planned for late FY2026.
Preparation for Phase 3 Bridging Study and Commercialization. GeoVax is preparing for an immune bridging study to show GEO-MVA stimulates an immune response that is non-inferior to a commercial Mpox vaccine. The study was designed to meet requirements for the European Medicines Agency’s expedited development pathway for Marketing Authorization.
Resolution Minerals Ltd (RLMLF/$0.04 | Price Target: $0.15) Mark Reichman [email protected] | (561) 999-2272 Hans Baldau [email protected] | Idaho’s Next Gold and Critical Minerals District Rating: OUTPERFORM
Initiating coverage with an Outperform. Resolution Minerals Ltd (ASX: RML, OTCQB: RLMLF) is advancing the Horse Heaven Gold–Antimony–Tungsten–Silver Project in Idaho, now covering 14,580 hectares. Following China’s December 2024 ban on antimony exports to the U.S., the country faces a structural supply deficit with no meaningful domestic mining or processing capacity. Resolution is positioned to address this gap through both resource development and intention to build a commercial-scale hydrometallurgical processing facility, aligning the project with U.S. policy priorities around domestic critical mineral supply chains.
Golden Gate. Phase 1 drilling at the Golden Gate Prospect confirmed a fault-controlled Intrusion Related Gold System with indications of meaningful scale. All 14 holes intersected mineralization from surface, including intercepts of 253m at 1.50 g/t Au, 265m at 0.60 g/t Au, and 189m at 1.30 g/t Au, all open at depth, while a second discovery at Golden Gate South expanded the mineralized footprint to more than 1.5km of strike. Importantly, the historical Golden Gate Tungsten Mine, last in production in 1980, is located within Resolution’s property boundary, with management evaluating a restart. A Phase 2 program of up to 45 diamond holes across 13,700 meters commences in early May 2026.
Leadership transition introduces seasoned external operator. The company announced that CEO Scott Buchanan has stepped down effective March 23, 2026, with founder Brandon Mintz stepping down as Executive Chairman and remaining on the Board in an advisory capacity. The Board appointed Alex Holmes as CEO and Chairman. Mr. Holmes brings relevant experience from his tenure as CEO of MoneyGram, particularly in payments infrastructure and regulatory compliance.
Transition comes at a pivotal time for the business. The leadership changes follow a quarter impacted by regulatory headwinds and ahead of a guided 30% to 40% decline in core BTM revenue in 2026. At the same time, the company is beginning to pursue new business initiatives, including its expansion into peer-to-peer betting and merchant cash advances. While the company noted the departures were not due to disagreements, in our view, the timing suggests the Board may be positioning the company for its next phase of execution as it navigates both regulatory pressure and early-stage diversification efforts.
Comstock (LODE/$2.78) Mark Reichman [email protected] | (561) 999-2272 Hans Baldau [email protected] | Review of 2025 and Outlook for 2026 Rating: MARKET PERFORM
A year of repositioning. During 2025, Comstock Inc. repositioned itself around two scalable growth businesses: Comstock Metals, which targets solar panel recycling and critical mineral recovery, and its investment in Bioleum Corporation, which is advancing biomass-based renewable fuels.
Near-term revenue visibility. Comstock Metals represents the most immediate catalyst for value creation. Comstock has validated a zero-landfill solar panel recycling process and completed permitting for its first industry-scale facility in Nevada, with operations expected to commence in the second quarter of 2026. The company has also secured logistics infrastructure and customer agreements across key U.S. regions, reflecting growing demand for end-of-life solar panel processing. Over time, the strategy could include multiple facilities and integrated refining capabilities that target recovery of higher-value metals such as silver.
First Phosphate Corp. (FRSPF/$0.69 | Price Target: $1.65) Mark Reichman [email protected] | (561) 999-2272 Hans Baldau [email protected] | NRCan Contribution Agreement Signed; Funding Secured Rating: OUTPERFORM
Investor webinar. CEO John Passalacqua recently presented to investors via Simone Capital. During the call, Mr. Passalacqua commented on the signed contribution agreement with Natural Resources Canada, the ongoing drill program and future feasibility study, the ADR launch, and the strength of the stock in recent weeks relative to a difficult broader market. Management attributed the stock’s resilience to the quality of the shareholder base, consistent milestone execution, and the visible de-risking effect of government backing.
NRCan contribution agreement signed. First Phosphate has executed a formal agreement with Natural Resources Canada providing up to C$16.7 million in non-repayable government funding under the Global Partnerships Initiative. The structure is a reimbursement model, whereby the company incurs eligible expenditures and receives reimbursement of up to 75% within approximately three months, supporting technical and engineering validation work through 2028. Combined with approximately C$20-C$22 million in cash on hand, we estimate total accessible financial resources of approximately C$36-C$38 million, sufficient to fund the company through drill completion, feasibility study, and final investment decision.
Ocugen (OCGN/$1.92 | Price Target: $12) Robert LeBoyer [email protected] | (212) 896-4625 Raising Price Target After Positive OCU410 Data Reported Rating: OUTPERFORM
Top-Line Phase 2 ArMaDa Trial Data Reported. Ocugen reported Phase 2 data for OCU410, its gene therapy for geographic atrophy in dry age-related macular degeneration (GA-dAMD). The data shows clinically meaningful and statistically significant benefit of 31% for treated patients compared with placebo. Based on the trial results, we are including OCU410 revenues in our FY2029 earnings model and raising our price target to $12 per share.
Results Show Preservation of Function and Cell Structure. The primary endpoint showed 31% reduction in lesion growth at the optimal dose (medium) group compared to controls (p< 0.05). A secondary endpoint of photoreceptor cell loss, correlating with visual function, showed a 27% slower rate compared to controls. In addition, 55% of treated patients demonstrated a lesion size reduction of greater than 30% compared with controls.
Solid Q4 results. The company reported Q4 revenue of $90.0 million and adj. EBITDA of $15.0 million. While revenue was modestly below our estimate of $99.0 million, adj. EBITDA was in line with our estimate of $15.1 million. Notably, the strong adj. EBITDA figure was largely driven by more efficient use of marketing spend, which decreased approximately 25% compared to the prior year period.
Key operating metrics. Bookings and monthly paying users (MPU) decreased by 7% and 10%, respectively, compared with the prior year period, but the decrease was expected as the company is focused on the quality of gameplay and retaining high-quality users. Furthermore, the company’s strategy appears to be paying off, as average bookings per paying user (ABPPU) increased from $102 in Q4’24 to $106 in Q4’25.
Noble Capital Markets Research Report Monday, March 23, 2026
Companies contained in today’s report:
1-800-Flowers.com (FLWS)/OUTPERFORM – Raising Rating: Unleashing AI To Drive Efficiency And Growth Eledon Pharmaceuticals (ELDN)/OUTPERFORM – FY2025 Reported With Tegoprubart Updates and Phase 3 Expectations Titan International (TWI)/OUTPERFORM – Production Consolidation
1-800-Flowers.com (FLWS/$3.01 | Price Target: $3.75) Michael Kupinski [email protected] | (561) 994-5734 Jacob Mutchler [email protected] | Raising Rating: Unleashing AI To Drive Efficiency And Growth Rating: OUTPERFORM
Highlights from a fireside chat. This report highlights a fireside chat with Adolfo Villagomez, CEO, who discussed the company’s four pillar initiative to transform the company into a more efficient, growth focused company.
Improving the company’s cost structure. Management has implemented a comprehensive review of the organization’s operations with the goal of reducing redundancies and improving productivity. The company is targeting approximately $50 million in run-rate cost savings across fiscal years 2026 and 2027, achieved through initiatives such as workforce streamlining, supply chain optimization, procurement improvements, and the reduction of organizational layers.
Eledon Pharmaceuticals (ELDN/$2.88 | Price Target: $10) Robert LeBoyer [email protected] | (212) 896-4625 FY2025 Reported With Tegoprubart Updates and Phase 3 Expectations Rating: OUTPERFORM
Tegoprubart Trials To Advance In FY2026. Eledon reported a 4Q loss of $10.4 million or $(0.11) per share and a FY2025 loss of $45.6 million or $(0.52) per share. The FY Total Operating Expenses were $83.3 million, with non-cash items (including changes in the fair value of warrant liabilities) of $33.4 million. Net Loss excluding these items would have been $79.1 million for full year. Updates for tegoprubart clinical development were also confirmed with the announcement. Cash on December 31, 2025 was $45.6 million.
Clinical Trials In Transplantation Have Several Milestones Ahead. Eledon expects to meet with the FDA to discuss plans for a Phase 3 tegoprubart trial for prevention of kidney transplant rejection. We expect the guidance to clarify required endpoints and could lead to the start of Phase 3 by year-end. Guidance is also expected for Islet cell transplantation in diabetes and xenotransplantation.
Titan International (TWI/$6.81 | Price Target: $11) Joe Gomes [email protected] | 561-999-2262 Production Consolidation Rating: OUTPERFORM
Consolidation. Last week, Titan announced a decision to consolidate production within its North American manufacturing footprint, which will result in the closure of its manufacturing facility in Jackson, Tennessee, by the end of October 2026. The Company expects production currently performed in Jackson to be transitioned to other existing Titan facilities over the coming months. We view this action as part of the Company’s ongoing efforts to optimize its manufacturing footprint and improve capacity utilization, given the uncertain operating environment.
Details. The Jackson closure is part of the ongoing synergies the Company expected to deliver from the Carlstar acquisition. The one-time costs for the plant closure and manufacturing relocation are estimated to be in the $7 million range, likely to hit in relatively equal amounts over the next three quarters. Estimated annual savings are in the $5 million range, with the full amount likely to begin in 2027.
Noble Capital Markets Research Report Friday, March 20, 2026
Companies contained in today’s report:
Euroseas (ESEA)/OUTPERFORM – Diversification into Specialized High-Reefer Containerships Kratos Defense & Security (KTOS)/OUTPERFORM – Awarded Another Significant Contract NN (NNBR)/OUTPERFORM – Moving Into Higher Return Verticals Sky Harbour Group (SKYH)/OUTPERFORM – Delivery Pipeline Supports Revenue Growth Outlook Snail (SNAL)/OUTPERFORM – Release Roadmap Shifts Focus To 2027
Euroseas (ESEA/$70.37 | Price Target: $90) Mark Reichman [email protected] | (561) 999-2272 Hans Baldau [email protected] | Diversification into Specialized High-Reefer Containerships Rating: OUTPERFORM
Two newbuilds. Euroseas announced contracts for the construction of two 2,800 TEU high-reefer containership newbuilds, with deliveries expected sequentially in the second and third quarters of 2028. The total acquisition price for each of the two newbuild vessels is $46.35 million, with financing expected to include a combination of debt and equity.
Strategic expansion. The vessels will be built to EEDI Phase 3 and IMO NOx Tier III standards and will be equipped with more than 1,000 reefer plugs, optimizing them for high-reefer-density trades. This enhances Euroseas’ exposure to growing refrigerated cargo demand. Importantly, the agreement includes options for up to four additional vessels of similar design, with either reefer or conventional configurations. In our view, this aligns with the company’s strategy of modernizing and diversifying its fleet, lowering the average age, and improving environmental efficiency.
Space Force. The Space Force’s Space Systems Command awarded Kratos a $447 million follow-on contract for Ground Management and Integration for the first two sets of Medium-Earth Orbit Missile Warning and Tracking satellites, according to a press release from the Agency. This follow-on award continues the positive award environment for Kratos, in our view.
Focus. SSC’s Resilient MWT MEO program under SYD 84 is focused on the rapid acquisition of robust infrared sensing technology and integrating it into an entirely new satellite constellation in MEO. The system is designed to detect and track a range of threats, from large, bright intercontinental ballistic missile launches to dim, maneuvering hypersonic missiles, integrating it with the broader national missile defense architecture
NN (NNBR/$1.48 | Price Target: $6) Joe Gomes [email protected] | 561-999-2262 Moving Into Higher Return Verticals Rating: OUTPERFORM
Data Centers. NN continues to grow its presence in the data center market, a key targeted growth market for the Company. The AI data center market fits precisely into NN’s decades of know-how in fluid management and Six Sigma quality levels. For NN, it is a strategic and straightforward application of existing know-how with managing gas, diesel, and hydraulic fluids and applying that know-how to managing cooling fluids.
Opportunity. NN has secured multiple new awards with a leading global provider of AI infrastructure and data center computing equipment. In response, NN is investing in a large installation of 17 next-generation high-speed, high-precision CNC machines that will meet and exceed requirements. This expansion and ramp-up is happening now across 2026. These machines will add to NN’s portfolio of over 100 of these similar machines already in-house.
Sky Harbour Group (SKYH/$9.47 | Price Target: $23) Patrick McCann [email protected] | (314) 724-6266 Michael Kupinski [email protected] | (561) 994-5734 Delivery Pipeline Supports Revenue Growth Outlook Rating: OUTPERFORM
Q4 results. Sky Harbour reported Q4 revenue of $8.1 million and an adj. EBITDA loss of $1.0 million compared with our estimates of $8.6 million and a loss of $0.4 million, respectively. Notably, the company reached an adj. EBITDA breakeven on a run-rate exiting December.
Leasing trends. Management highlighted lease-up progress at Phoenix, Dallas, and Denver, with the former two ahead of expectations and Denver improving after a slower start. The company also emphasized growing use of pre-leasing, targeting roughly 50% of a campus leased by opening.
Snail (SNAL/$0.62 | Price Target: $2.75) Michael Kupinski [email protected] | (561) 994-5734 Jacob Mutchler [email protected] | Release Roadmap Shifts Focus To 2027 Rating: OUTPERFORM
Q4 results in line with expectations. Revenue of $25.1M and adj. EBITDA loss of $1.3 million was better than our expectations of $23.0 million and a loss estimate of $1.77 million, respectively. The quarter was supported by deferred revenue recognition and strong sequential revenue improvement.
ARK franchise momentum remains strong, with ASA surpassing 4M units sold and continued engagement across ASA, ASE, and ARK Mobile, reinforcing long-term durability. There appears to be a robust multi-year content pipeline which provides visibility, though updated timing shifts a portion of expected revenue and adj. EBITDA from 2026 into 2027.
Noble Capital Markets Research Report Thursday, March 19, 2026
Companies contained in today’s report:
Kuya Silver (KUYAF)/OUTPERFORM – Driving Mineral Resource Growth Perfect (PERF)/OUTPERFORM – Founder-Led Take-Private Proposal SelectQuote (SLQT)/OUTPERFORM – Launching Franchise-Based Distribution Channel Star Equity Holdings, Inc. (STRR)/OUTPERFORM – Fourth Quarter 2025 Results
Kuya Silver (KUYAF/$0.52 | Price Target: $3.5) Mark Reichman [email protected] | (561) 999-2272 Hans Baldau [email protected] | Driving Mineral Resource Growth Rating: OUTPERFORM
Kuya Silver is significantly scaling its exploration efforts at Bethania. The company has expanded its fully funded 2026 drill program to approximately 20,000 meters, making it the largest drilling campaign in the project’s history. By combining 10,000 meters of surface and 10,000 meters of underground drilling, Kuya seeks to extend known mineralization near existing operations and test new district scale targets, positioning the project for meaningful resource growth.
High-grade regional targets highlight strong expansion potential. Exploration has identified multiple vein systems beyond the current mine area, with high priority prospects such as Millococha, Tito PH, and Carmelitas demonstrating encouraging grades and geological continuity. These areas, supported by historic artisanal mining and recent sampling, suggest the presence of a broader mineralized system that could materially increase the overall resource base
Take Private Proposal. Perfect Corp. received a preliminary, non-binding proposal from a consortium led by CEO Alice H. Chang and CyberLink to take the company private at $1.95 per share. The transaction would be funded through rollover equity, company cash, and potential debt. The board intends to form a special committee to evaluate the proposal, and there is no assurance that a transaction will be completed.
Ownership structure supports a high likelihood of completion. The consortium controls approximately 53.4% of shares and 81.2% of voting power. In our view, this significantly increases the likelihood of a transaction, subject to special committee approval.
SelectQuote (SLQT/$0.61 | Price Target: $5) Patrick McCann [email protected] | (314) 724-6266 Michael Kupinski [email protected] | (561) 994-5734 Launching Franchise-Based Distribution Channel Rating: OUTPERFORM
SelectQuote Local. SelectQuote announced SelectQuote Local, a new franchise model designed to complement its core telephonic insurance distribution platform by offering in-person sales and support. Management indicated the initiative leverages the company’s existing marketing, technology, and carrier relationships, positioning it as a natural extension of the platform rather than a shift in strategy.
Complementary model and TAM expansion. In our view, SelectQuote Local is unlikely to cannibalize the company’s core call center operations, as it targets a distinct subset of consumers who prefer in-person engagement. We believe the company can leverage excess lead flow and brand recognition to support early franchise success without significant incremental marketing investment. Additionally, we expect the in-person model could enhance cross-sell opportunities with Healthcare Services, as local relationships may improve customer engagement and trust.
Star Equity Holdings, Inc. (STRR/$9.6 | Price Target: $16) Joe Gomes [email protected] | 561-999-2262 Fourth Quarter 2025 Results Rating: OUTPERFORM
Overview. Star Equity’s fourth quarter and full-year financial results reflect positive momentum and improvement over the prior year quarter, largely driven by the August 2025 merger. Overall, 2025 was a transformational year for Star. The merger strengthened the Company’s operating and financial position and accelerated the growth strategy.
4Q25 Results. Fourth quarter 2025 revenue of $56.8 million rose 69% y-o-y, but was slightly below our $58 million estimate. Adjusted EBITDA increased to $2.2 million versus $0.9 million last year. We had projected $2.3 million. Adjusted net loss was $0.10/sh, compared to adjusted net income of $0.04/sh in 4Q24.
Noble Capital Markets Research Report Wednesday, March 18, 2026
Companies contained in today’s report:
Century Lithium Corp. (CYDVF)/OUTPERFORM – Updated Feasibility Study Highlights Incremental Value Greenwich LifeSciences, Inc. (GLSI)/OUTPERFORM -Preliminary Phase 3 FLAMINGO-01 Update Shows Reduction In Breast Cancer Recurrence Rate Gyre Therapeutics, Inc (GYRE)/OUTPERFORM – Priority Review Received For Hydronidone In China Snail (SNAL)/OUTPERFORM – Quarterly Preview: Strategic Updates Provided At GDC Summit Midstream Corp (SMC)/OUTPERFORM – Double E Pipeline Underpins Favorable Growth Outlook
Century Lithium Corp. (CYDVF/$0.27 | Price Target: $3.05) Mark Reichman [email protected] | (561) 999-2272 Hans Baldau [email protected] | Updated Feasibility Study Highlights Incremental Value Rating: OUTPERFORM
Updated feasibility study. Century recently filed its updated 2026 NI 43-101 feasibility study for its 100%-owned Angel Island Lithium Project in Nevada. The updated study reflects engineering optimization and improvements that materially strengthen the project’s economic profile and highlight Angel Island as one of the most significant and economically robust sedimentary lithium developments in the United States.
Lower initial capital expenditures. Phase I initial capital expenditures are estimated to be $997 million, a significant reduction from the $1.5 billion outlined in the 2024 Study. The updated study streamlines development into a two-phase approach. Phase I contemplates 7,500 tonnes per day (tpd) of mill feed, expanding to 15,000 tpd in Phase II beginning in Year 5. Phase II expansion capital is estimated at $660 million. A previously planned third expansion phase was eliminated, lowering overall capital requirements. The economic analysis is based on a 40-year production schedule, with planned life-of-mine average production of 26,500 tonnes per annum of battery-grade lithium carbonate.
Greenwich LifeSciences, Inc. (GLSI/$30.05 | Price Target: $45.00) Robert LeBoyer[email protected] | (212) 896-4625 Preliminary Phase 3 FLAMINGO-01 Update Shows Reduction In Breast Cancer Recurrence Rate Rating: OUTPERFORM
New Analysis Shows Less Than 1% Recurrence Rate. Greenwich Pharmaceuticals announced a preliminary update from its FLAMINGO-01 trial. The data from the open-label arm of the trial showed a recurrence rate of less than 1% per year compared to a recurrence rate of 4% per year for patients treated with Kadcyla (ado-trastuzumab emtansine or T-DM1, from Genentech) in the Phase 3 KATHERINE Study. This is a 70% to 80% reduction in the historical recurrence rate for these patients.
Background On The Phase 3 FLAMINGO-01 Trial. The trial tests GLSI-100, an immunotherapy to prevent recurrence of HER2-positive breast cancer. Its design has a doubleblind portion that enrolls patients with the immune marker HLA-A02 to receive either GLSI-100 or placebo, and an open-label arm that enrolls patients that have other HLA types (non-HLAA02). The new data is from the open-label arm of the trial.
Gyre Therapeutics, Inc (GYRE/$7.49 | Price Target: $20.00) Robert LeBoyer[email protected] | (212) 896-4625 Priority Review Received For Hydronidone In China Rating: OUTPERFORM
Gyre Receives Priority Review. Hydronidone has been awarded Priority Review Status by the Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA). This is consistent with our expectations for an accelerated NDA review and late FY2026 approval for Hydronidone.
Meeting With The CMPA Was Positive. In early January, Gyre Pharmaceuticals (China) held a Pre-New Drug Application meeting with the CDE. At that time, the CDE agreed that data from the Hydronidone Phase 3 trial for treating chronic hepatitis B (CHB)-associated liver-fibrosis supported an application for conditional approval. It also met the criteria for Priority Review.
Snail (SNAL/$0.61 | Price Target: $3) Michael Kupinski [email protected] | (561) 994-5734 Jacob Mutchler [email protected] | Quarterly Preview: Strategic Updates Provided At GDC Rating: OUTPERFORM
Strategic updates ahead of Q4 Earnings Call. At the Game Developers Conference (GDC) in San Francisco last week, the company provided updates across its game portfolio, outlining a steady pipeline of ARK franchise releases, expansions for existing titles, and new indie projects. The announcements were delivered ahead of the company’s Q4 and full-year 2025 earnings call scheduled for March 19, 2026, at 4:30 p.m. ET, providing a preview of its strategic product developments.
Strong Early Access sales. Notably, Bellwright has surpassed 1 million units sold on Steam during Early Access, demonstrating strong player engagement ahead of its 1.0 launch and planned expansion to Xbox and PlayStation. As a reminder, development is now fully in-house following the acquisition and integration of Donkey Crew, the Poland-based studio behind Bellwright, strengthening the franchise’s long-term potential.
Summit Midstream Corp (SMC/$30.73 | Price Target: $48.5) Mark Reichman [email protected] | (561) 999-2272 Hans Baldau [email protected] | Double E Pipeline Underpins Favorable Growth Outlook Rating: OUTPERFORM
Double E Pipeline growth. Summit recently signed two new long-term take-or-pay agreements totaling 540 MMcf/d of incremental firm capacity on the Double E Pipeline, an 11-year, 210 MMcf/d contract with a large investment-grade shipper and an 11-year, 230 MMcf/d agreement with an undisclosed shipper, alongside the previously announced 100 MMcf/d Producers Midstream II commitment, which received an affirmative FID during the quarter. These contracts are expected to grow the Permian Segment Adj. EBITDA from ~$34 million in 2025 to ~$60 million by 2029.
2026 guidance. Summit expects full-year 2026 Adj. EBITDA of $225 million to $265 million, with total capital expenditures of $85 million to $105 million, including approximately $35 million attributable to Double E. The outlook assumes WTI at approximately $64 per barrel and Henry Hub at approximately $3.40 per MMBtu, both materially below current strip prices, suggesting meaningful upside if the commodity environment is sustained. The company expects 116 to 126 well connections supported by seven active rigs and approximately 90 DUCs.
Noble Capital Markets Research Report Tuesday, March 17, 2026
Companies contained in today’s report:
Bitcoin Depot (BTM)/OUTPERFORM – Wave of Regulatory Action Weighs on Outlook NeuroSense Therapeutics Ltd. (NRSN)/OUTPERFORM – Phase 2b PARADIGM Study Published In JAMA Neurology Townsquare Media (TSQ)/OUTPERFORM – Were We On The Same Investor Call?
Bitcoin Depot (BTM/$4.03 | Price Target: $13) Patrick McCann [email protected] | (314) 724-6266 Michael Kupinski [email protected] | (561) 994-5734 Wave of Regulatory Action Weighs on Outlook Rating: OUTPERFORM
Q4 results. Bitcoin Depot reported Q4 revenue of $116.0 million, above our estimate of $112.0 million, reflecting somewhat stronger transaction activity than anticipated despite emerging regulatory headwinds. Adj. EBITDA of $1.6 million was below our forecast of $2.5 million due to higher operating expenses during the quarter.
Initial steps toward revenue diversification. The company is beginning to expand beyond the core Bitcoin ATM network through new fintech initiatives. It recently acquired Kutt, a peer-to-peer social betting platform, and launched ReadyBucks, a merchant cash advance platform targeting small businesses and gig workers. Management indicated that both initiative are starting small and not expected to materially impact near-term revenue.
NeuroSense Therapeutics Ltd. (NRSN/$0.81 | Price Target: $9) Robert LeBoyer [email protected] | (212) 896-4625 Phase 2b PARADIGM Study Published In JAMA Neurology Rating: OUTPERFORM
Presigious Journal Publishes The Phase 2b PARDIGM Study. JAMA Neurology has published an article dissussing the Phase 2b PARDIGM clinical trial. This peer-reviewed journal is published by the American Medical Association and regarded as one of the most prestigious journals in the field of neurology. We see this as a validation the clinical results and an acknowledgement of the impact PrimeC had on the amyotrophic lateral sclerosis (ALS) patients in the study.
PrimeC Addresses Important Mechanisms Of Neuron Degeneration. PrimeC is a proprietary fixed-dose oral combination of celecoxib and ciprofloxacin. These drugs target pathways of neuronal cell death, including regulation of microRNA synthesis, reduction in neuroinflammation, and modulation of iron accumulation. Additional testing by NeuroSense determined the optimal dosage combination of the two drugs for human studies and the extended releaase formulaton.
Townsquare Media (TSQ/$6.14 | Price Target: $15) Michael Kupinski [email protected] | (561) 994-5734 Jacob Mutchler [email protected] | Were We On The Same Investor Call? Rating: OUTPERFORM
In-line Q4 results. The company reported Q4 revenue and adj. EBITDA of $106.5 million and $21.5 million, both of which were in line with our estimates of $106.1 million and $22.0 million, respectively. Notably, the company continued to face headwinds in its digital businesses, which have been its primary growth engine.
Advertising trends appear to be improving. Digital revenues remained the company’s largest contributor and primary growth engine, representing approximately 55% of total revenue in 2025, up from 52% in 2024, and generated 56% of segment profit, compared with 50% a year earlier. Despite the stronger mix, fourth quarter Digital Advertising revenue declined 1%, as weakness in remnant advertising offset growth in direct-sold and programmatic digital advertising.
Noble Capital Markets Research Report Monday, March 16, 2026
Companies contained in today’s report:
MariMed Inc (MRMD)/OUTPERFORM – Reports Fourth Quarter and Full Year Results ONE Group Hospitality (STKS)/OUTPERFORM – Fourth Quarter In-line with Pre-announced Results Tonix Pharmaceuticals (TNXP)/OUTPERFORM – Tonix Reports FY2025 With Tonmya Sales and Pipeline Updates
MariMed Inc (MRMD/$0.08 | Price Target: $0.25) Joe Gomes [email protected] | 561-999-2262 Reports Fourth Quarter and Full Year Results Rating: OUTPERFORM
Overview. For the full year 2025, MariMed reported record revenue as well as the sixth consecutive year of positive adjusted EBITDA. Wholesale was once again the star performer, with sales increasing 11% y-o-y. MariMed increased its distribution footprint penetration to 85% of the dispensaries in its core markets.
4Q25 Results. Revenue of $41.7 million rose 7.2% y-o-y and exceeded our $40.5 million estimate. Better than expected retail sales drove the results. Adjusted gross margin came in at 39.9% versus 43.2% last year. Adjusted EBITDA totaled $4.4 million, down from $5.9 million in 4Q24. MariMed reported adjusted net income of $2.2 million, compared to a net loss of $3.1 million in 4Q24.
ONE Group Hospitality (STKS/$1.72 | Price Target: $5) Joe Gomes [email protected] | 561-999-2262 Fourth Quarter In-line with Pre-announced Results Rating: OUTPERFORM
Overview. Fourth quarter and full year 2025 results came in-line with management’s January 12, 2026 pre-announcement, with fourth quarter revenue of $207 million and full year revenue of $806 million. Notably, all brands demonstrated a sequential improvement in comparable sales during the quarter. Fourth quarter consolidated comparable sales declined approximately 1.8%, representing about 4 points of sequential improvement from the third quarter. And this momentum has continued in the new year.
4Q25 Results. For the fourth quarter, total GAAP revenue was approximately $207 million compared to $222 million in the prior year quarter. Adjusted EBITDA was $28.1 million compared to $31 million in the prior year quarter, a decrease of 9.5%. ONE Group reported a net loss, before preferred stock dividends, of $6.4 million compared to net income of $1.6 million in 4Q24.
Tonix Pharmaceuticals (TNXP/$13.24 | Price Target: $34) Robert LeBoyer [email protected] | (212) 896-4625 Tonix Reports FY2025 With Tonmya Sales and Pipeline Updates Rating: OUTPERFORM
Tonix Reported Initial Tonmya Launch Results. Tonix reported a 4Q loss of $46.9 million or $(3.98) per share and a FY2025 loss of $124 million or $(14.57) per share. Initial sales of Tonmya for the six-week period after launch were $1.4 million, with total 4Q product sales of $5.4 million and FY2025 sales of $13.1 million. The company also gave updates on additional Tonmya indications and clinical trial progress. Total cash and equivalents balance on December 31, 2025 was $207.6 million.
Tonmya Sales Began In Mid-November. Sales of Tonmya (TNX-102 SL) started in November 2025 and recorded $1.4 million in 4Q. The company has 90 sales reps and reported meeting its expectations for the 14-week period through February 2026. Over 1,500 health care providers have written prescriptions for over 2,500 patients, with 4,200 prescriptions written. We believe this is an early indication of repeat use by the patients.
Noble Capital Markets Research Report Friday, March 13, 2026
Companies contained in today’s report:
Gyre Therapeutics, Inc (GYRE)/OUTPERFORM – 4Q25 Report Meets Expectations As A Transition Year Begins Hemisphere Energy (HMENF)/NOT RATED – Discontinuing Research Coverage Saga Communications (SGA)/OUTPERFORM – Stepping Up Digital Investments Seanergy Maritime (SHIP)/OUTPERFORM – Fleet Expansion Continues; Squireship Sale Summit Midstream Corp (SMC)/OUTPERFORM – Summit to Host FY2025 Earnings Call on March 17 The Oncology Institute, Inc. (TOI)/OUTPERFORM – Strong Results Driven By Covered Population Growth With Improving Margins
Gyre Therapeutics, Inc (GYRE/$7.81 | Price Target: $20) Robert LeBoyer [email protected] | (212) 896-4625 4Q25 Report Meets Expectations As A Transition Year Begins Rating: OUTPERFORM
4Q25 Revenues Showed Modest Increase. Gyre reported a 4Q loss of $1.7 million or $(0.02) per share and profit of $5.0 million or $0.06 per basic share and $0.02 per fully diluted share. Revenues of $116.6 million increased 10.2% over the $105.8 million in FY2024. These results are consistent with our view that FY2026 is a transition year, as the company focuses on approval and launch of Hydronidone plus the acquisition of Cullgen, Inc, adding its degrading protein technology platform (discussed in our Research Note on March 3).
Product Sales and Financials. FY2025 revenue of $116.6 million was driven by continued sales of Etuary and new product launches. Etuary sales of $106.1 million for FY2026 compare with $105.0 million in 4Q25. During the year, Gyre launched Contiva (avatrombopag maleate tablet) in March 2025 and Etorel (nintedanib ethanesulfonate capsules) in June 2025. Contiva sales were $5.5 million and Etorel sales were $4.6 million for the full year. The company expects the National Drug Procurement Program in China and market conditions to lower sales of $100.5 million to $111.0 million.
Saga Communications (SGA/$11.09 | Price Target: $18) Michael Kupinski [email protected] | (561) 994-5734 Jacob Mutchler [email protected] | Stepping Up Digital Investments Rating: OUTPERFORM
Q4 Results. The company reported Q4 revenue and adj. EBITDA of $26.5 million and $0.8 million, respectively, modestly below our estimates of $27.7 million and $2.0 million, as illustrated in Figure #1 Q4 Results. Results were impacted by softness in traditional broadcast revenue, while digital Interactive revenue remained a bright spot, increasing 25.8% y-o-y.
Strong digital results. The company continued to implement its blended digital-radio strategy, integrating broadcast and digital solutions to enhance advertiser engagement and retention. Total Interactive revenue reached $4.3 million, an increase of 25.8% year over year, with full year growth reaching 19.1%. Furthermore, the growth was driven by several verticals, including search advertising, targeted display, and e-commerce platforms, reflecting growing adoption of integrated radio and digital advertising campaigns.
Seanergy Maritime (SHIP/$12.68 | Price Target: $18) Mark Reichman [email protected] | (561) 999-2272 Hans Baldau [email protected] | Fleet Expansion Continues; Squireship Sale Rating: OUTPERFORM
Newbuild program expands to five vessels. Seanergy announced the acquisition of two Japanese newbuild scrubber-fitted 181,500 dwt Capesize vessels, expanding the total newbuild program to five vessels, including four Capesize vessels and one Newcastlemax, with a combined contract value of approximately $384 million. The first Japanese vessel is a direct purchase with delivery expected between Q2 and Q3 2027, while the second is structured as a 10-year bareboat-in contract with a Q1 2029 delivery and a purchase option beginning at year five. The combined cost of both Japanese vessels is approximately $158 million.
Sale of M/V Squireship. Seanergyagreed to sell the 2010-built, 170,018 dwt M/V Squireship to a related party for $29.5 million with delivery expected between late April and early June 2026. The transaction is expected to generate net proceeds of approximately $13.5 million after debt repayment and produce an accounting gain of roughly $4 million. The sale is consistent with management’s capital recycling strategy, monetizing an older vessel at an attractive valuation while funding the newbuilding program and reducing average fleet age.
Summit Midstream Corp (SMC/$30.87 | Price Target: $47) Mark Reichman [email protected] | (561) 999-2272 Hans Baldau [email protected] | Summit to Host FY2025 Earnings Call on March 17 Rating: OUTPERFORM
Fourth quarter and FY2025 financial results. Summit will report operating and financial results after the market close on Monday, March 16. Management will host a teleconference at 10 am ET on Tuesday, March 17. We anticipate management will provide its outlook and corporate guidance for 2026.
Noble estimates. We forecasted fourth quarter and FY2025 EBITDA of $62.5 million and $246.6 million, respectively, and net losses of $0.4 million, or $(0.00) per share, and $11.5 million, or $(0.95) per share. Our fourth quarter and full year revenue estimates are $146.7 million and $566.5 million, respectively. Recall management previously communicated that it expected adjusted EBITDA to be at the low end of its $245 million to $280 million 2025 guidance range. For 2026, we are projecting revenue, EBITDA, net income and EPS of $591.3 million, $265.7 million, $12.7 million, and $1.03, respectively.
The Oncology Institute, Inc. (TOI/$2.62 | Price Target: $8) Robert LeBoyer [email protected] | (212) 896-4625 Strong Results Driven By Covered Population Growth With Improving Margins Rating: OUTPERFORM
4Q25 Had Strong Revenue Growth. The Oncology Institute reported a 4Q25 loss of $7.5 million or $(0.06) per share and a FY2026 loss of $60.6 million or $(0.54) per share. Importantly, 4Q25 Revenues of $142.0 million were up 41.6% over 4Q24, close to our estimate of $142.4 million, with a slightly different mix from Patient Services and Dispensary Revenues. EBITDA in 4Q25 was $0.15 million, turning positive for the first time, and compares with $(7.8) million in 4Q24. Cash balance on December 31, 2025 was $33.6 million.
Margins Improved During 4Q and For FY2025. Overall Gross Margin for 4Q2025 improved to 16.0% of revenues compared with 14.6% in 4Q2024. This reflects margins improvements in Patient Services of 11.9% compared with 8.9% in 4Q24, and Dispensary margins of 18.1% compared with 16.9% in 4Q24. FY2025 Overall Gross Margin was 15.2% compared with 13.7% for FY2024.
Noble Capital Markets Research Report Thursday, March 12, 2026
Companies contained in today’s report:
ACCO Brands (ACCO)/OUTPERFORM – Fourth Quarter and Full year 2025 Results Commercial Vehicle Group (CVGI)/OUTPERFORM – Making Progress
ACCO Brands (ACCO/$3.51 | Price Target: $9) Joe Gomes [email protected] | 561-999-2262 Fourth Quarter and Full year 2025 Results Rating: OUTPERFORM
Overview. Despite continued demand challenges globally and tariff-related disruptions in the U.S., ACCO maintained or grew its market position in most categories, demonstrating the resilience and strength of the brand portfolio. ACCO delivered sales and adjusted EPS in-line with management’s outlook.
4Q25 Results. Net sales were $428.8 million, down 4.3% y-o-y, reflecting soft global demand for certain products, partially offset by growth in gaming accessories. We were at $435 million. Comp sales were down 7.8%. Adjusted EBITDA totaled $68.6 million, or a 16% margin, compared to $73.6 million and 16.4%, respectively, in 4Q24. ACCO reported adjusted EPS of $0.38, flat with the $0.39 reported in 4Q24. We were at $0.38.
Commercial Vehicle Group (CVGI/$2.03 | Price Target: $4) Joe Gomes [email protected] | 561-999-2262 Making Progress Rating: OUTPERFORM
Overview. CVG delivered strong year-over-year improvement in profitability despite a challenging demand environment, particularly in the North American Class 8 truck market. The continued year-over-year improvement in profitability was again driven by management’s focus on operational efficiency improvement. Another highlight of the quarter is the continued strong performance within the Global Electrical Systems segment. During the third quarter, CVG saw segment performance inflect with revenues up 6% compared to the prior year. The fourth quarter saw further acceleration, with revenues up 13% y-o-y.
4Q25 Results. Fourth quarter revenue of $154.8 million was down 5.2% y-o-y, due primarily to North American demand. Adjusted EBITDA was $2.3 million, up 155.6%, with an adjusted EBITDA margin of 1.5% versus 0.6% last year. Adjusted net loss was $0.18/sh, compared to an adjusted net loss of $0.15/sh in 4Q24.
Noble Capital Markets Research Report Wednesday, March 11, 2026
Companies contained in today’s report:
FreightCar America (RAIL)/OUTPERFORM – FY2025 Review and Estimate Update NN (NNBR)/OUTPERFORM – Toward a Brighter Future Power Metallic Mines Inc. (PNPNF)/OUTPERFORM – High-Grade Lion Drilling Continues to Expand Near-Surface Potential The Beachbody Company (BODI)/OUTPERFORM – Turnaround Complete, Growth Phase Begins
FreightCar America (RAIL/$10.01 | Price Target: $16.5) Mark Reichman [email protected] | (561) 999-2272 Hans Baldau [email protected] | FY2025 Review and Estimate Update Rating: OUTPERFORM
FY2025 financial results. FreightCar America generated 2025 adjusted earnings per share (EPS) of $0.50 per share compared to $0.15 per share in 2024. Gross margin as a percentage of revenue increased to 14.6% compared to 12.0% in FY2024. Revenue and rail car deliveries decreased to $501.0 million and 4,125, respectively, compared to $559.4 million and 4,362 in 2024. Adjusted EBITDA increased to $44.8 million compared to $43.0 million in 2024. Full year adjusted free cash flow amounted to $31.4 million versus $21.7 million in 2024.
FY2026 corporate guidance. Railcar deliveries are expected to be in the range of 4,000 to 4,500, revenue in the range of $500 to $550 million, and adjusted EBITDA of $41 to $50 million. Guidance for 2026 adj. EBITDA reflects facility lease expenses recorded in cost of goods sold instead of previously classified within interest expense. On a lease-adjusted basis, 2025 adj. EBITDA was $41.2 million.
NN (NNBR/$1.3 | Price Target: $6) Joe Gomes [email protected] | 561-999-2262 Toward a Brighter Future Rating: OUTPERFORM
Momentum. NN is bringing solid momentum into 2026. A number of end markets are showing improvement, including the commercial vehicle market, where orders continue to show year-over-year strength. Management noted on the call that the electric grid, data center, defense, and electronics sectors are all growing in the first quarter and are expected to grow in the full year 2026.
Improved Margins. As the business mix moves up the value chain, NN is experiencing higher margins. Adjusted gross margin performance was 18.8% in the fourth quarter and 18.5% for the full year, which again has NN trending towards management’s five year goal of 20% consolidated gross margins.
Power Metallic Mines Inc. (PNPNF/$0.87 | Price Target: $2.65) Mark Reichman [email protected] | (561) 999-2272 Hans Baldau [email protected] | High-Grade Lion Drilling Continues to Expand Near-Surface Potential Rating: OUTPERFORM
Best copper intercept to date. Power Metallic reported results from the first hole of the 2026 winter drill campaign. Hole PML-26-049 intersected 16.55 meters grading 10.08% copper (15.11% CuEq) within massive to brecciated copper sulphides, representing the strongest copper intersection reported at the Lion Zone to date. The hole was drilled to support interpretation of near-surface mineralization and to expand the deposit’s footprint in an area that management believes may be amenable to open-pit extraction.
Infill drilling is supportive. Results from holes PML-26-049 and PML-25-047 confirm strong grade continuity within the modeled Lion Zone geometry, improving confidence that portions of the deposit may ultimately support Indicated Resource classification. Deeper drilling has also expanded high-grade lenses within the system, including 7.60 meters grading 7.30% CuEq within an 18.0-meter interval grading 3.18% CuEq, further extending mineralization within the Lion zone.
The Beachbody Company (BODI/$8.33 | Price Target: $15) Michael Kupinski [email protected] | (561) 994-5734 Jacob Mutchler [email protected] | Turnaround Complete, Growth Phase Begins Rating: OUTPERFORM
Q4 results exceeded expectations. Q4 revenue of $55.5 million and adjusted EBITDA of $12.9 million, surpassed our estimates of $53.0 million and $5.0 million, respectively. Although revenue declined 7.3% sequentially and 35.7% year over year due to the continued wind-down of the legacy MLM model, operating income reached $8.2 million, marking the second consecutive profitable quarter and a $41.1 million year-over-year improvement.
Lean cost structure continues to drive strong operating leverage and profitability. Consolidated gross margin expanded 400 basis points year over year to 74.5%, supported by improved operational efficiency and lower digital amortization costs. Total operating expenses declined 64.6% year over year to $33.2 million as restructuring initiatives and the elimination of MLM-related costs materially reduced SG&A. As a result, the company generated $5.2 million in net income and its ninth consecutive quarter of positive adjusted EBITDA.
FreightCar America (RAIL/$12.68 | Price Target: $18) Mark Reichman [email protected] | (561) 999-2272 Hans Baldau [email protected] | Q4′ 2025 Financial Results Below Our Estimates Rating: OUTPERFORM
Q4′ 2025 financial results. RAIL generated Q4′ 2025 adj. net income of $4.9 million or $0.16 per share, compared to net income of $8.0 million or $0.21 per share in Q4′ 2024. We had projected net income of $6.1 million or $0.18 per share. Gross margin as a percentage of revenue decreased to 13.4% compared to 15.3% in Q4′ 2024 and our estimate of 14.0%. Revenue declined to $125.6 million compared to $137.7 million during the prior year period, while rail car deliveries increased to 1,172 compared to 1,019 units. We had projected rail car deliveries of 1,557 and revenue of $139.9 million. Adj. EBITDA declined to $10.4 million compared to $13.9 million in Q4′ 2024. We had forecasted adj. EBITDA of $12.5 million.
FY2026 corporate guidance. Railcar deliveries are expected to be in the range of 4,000 to 4,500, revenue in the range of $500 to $550 million, and adjusted EBITDA of $41 to $50 million. In FY2025, railcar deliveries were 4,125, revenue amounted to $501.0 million, and adjusted EBITDA totaled $44.8 million. FY2026 guidance is below our current 2026 estimates. Following relatively soft industry orders during the fourth quarter of 2025, we think management is taking a conservative view based on an increasingly uncertain economic outlook and an EOY 2025 backlog of 1,926 units valued at $137.5 million. Moreover, 2026 adj. EBITDA guidance reflects facility lease expenses recorded in cost of goods sold instead of previously classified within interest expense. On a lease-adjusted basis, 2025 adj. EBITDA was $41.2 million.
Solid Q4 results. The company reported Q4 revenue of $90.0 million and adj. EBITDA of $15.0 million. While revenue was modestly below our estimate of $99.0 million, adj. EBITDA was in line with our estimate of $15.1 million, as illustrated in Figure #1 Q4 Results. Notably, the strong adj. EBITDA figure was largely driven by more efficient use of marketing spend, which decreased approximately 25% y-o-y.
Key operating metrics. Bookings and monthly paying users (MPU) decreased by 7% and 10%, respectively, compared with the prior year period, but the decrease was expected as the company is focused on the quality of gameplay and retaining high-quality users. Furthermore, the company’s strategy appears to be paying off, as average bookings per paying user (ABPPU) increased from $102 in Q4’24 to $106 in Q4’25.
Viewership Milestone. The company announced that more than four million viewers tuned in to its broadcast and streaming platforms for its live coverage of the President’s State of the Union address on February 24. Notably, the Newsmax channel garnered 2.8 million total viewers, with an additional 1.3 million streaming the coverage on Newsmax2. The strong viewership marked a major ratings and digital engagement milestone, reflecting the network’s growing reach across traditional and digital platforms.
Ratings Leadership. The network’s total audience exceeded the combined viewership of Fox Business, CNBC, and NewsNation by 23%. Throughout the evening, the Newsmax team provided continuous updates on Newsmax.com and engaged more than 23 million social media followers. Additionally, a wide range of lawmakers, administration officials, and political commentators joined the network on both broadcast and streaming coverage.
Noble Capital Markets Research Report Monday, March 9, 2026
Companies contained in today’s report:
Bit Digital (BTBT)/OUTPERFORM – February Ethereum Metrics Information Services Group (III)/OUTPERFORM – AI Demand Drives Solid Results
Bit Digital (BTBT/$1.62 | Price Target: $5.5) Joe Gomes [email protected] | 561-999-2262 February Ethereum Metrics Rating: OUTPERFORM
Data. Bit Digital reported its monthly Ethereum (“ETH”) treasury and staking metrics for the month of February 2026. As of month end, the Company held approximately 155,434 ETH versus 155,239 ETH at the end of January. Included in the ETH holdings were approximately 15,283 ETH and ETH-equivalents held in an externally managed fund. The Company’s total staked ETH was approximately 138,269, or about 89% of its total holdings as of February 28th.
Yield and Value. Staking operations generated approximately 314 ETH in rewards during the period, representing an annualized yield of approximately 2.7%. Based on a closing ETH price of $1,965, as of February 28, 2026, the market value of the Company’s ETH holdings was approximately $305.4 million.
Information Services Group (III/$4.53 | Price Target: $6.5) Joe Gomes [email protected] | 561-999-2262 Jacob Mutchler [email protected] | AI Demand Drives Solid Results Rating: OUTPERFORM
Q425. Operating performance in 4Q25 was solid and came in at the upper end of management’s guidance. Revenue came in at $61.2 million, up 6% y-o-y. Adjusted EBITDA grew 24% to $8.1 million, and adjusted EBITDA margin expanded 189 basis points to 13.2%. ISG reported GAAP net income of $2.6 million, or EPS of $0.05/sh, compared to $3.0 million, or EPS of $0.06/sh, last year, which included a $2.3 million gain from the sale of the automation unit. Adjusted EPS was $0.08 versus $0.06 last year.
AI and Recurring Revenue. Management noted AI-related activities represented nearly 35% of quarterly revenue, up from approximately 10% a year ago. For the full year, AI-related revenue accounted for nearly 30% of total revenue, roughly three times last year’s proportion. Recurring revenue totaled $112 million, representing 46% of annual revenue, while recurring revenues grew 13% year-over-year in the fourth quarter. We expect both AI-related and recurring revenue to increase going forward.
Noble Capital Markets Research Report Friday, March 6, 2026
Companies contained in today’s report:
FreightCar America (RAIL)/OUTPERFORM – RAIL To Host FY2025 Earnings Call on March 10 InPlay Oil (IPOOF)/OUTPERFORM – Pembina Assets Shine, Disciplined Outlook
FreightCar America (RAIL/$13.15 | Price Target: $18) Mark Reichman [email protected] | (561) 999-2272 RAIL To Host FY2025 Earnings Call on March 10 Rating: OUTPERFORM
Fourth quarter and FY2025 earnings. FreightCar will release its fourth quarter and FY2025 financial results after the market close on Monday, March 9. Management will host an investor teleconference and webinar on Tuesday, March 10, at 11:00 am ET. We expect management to release corporate guidance for FY2026 railcar deliveries, revenue, and adjusted EBITDA. In addition to a market outlook, we think management will discuss its strategy for growing its aftermarket parts business along with its plans to enter the tank car market.
Noble estimates. Our fourth quarter 2025 revenue, EBITDA, and adjusted EPS estimates are $139.9 million, $12.5 million, and $0.18, respectively. For FY2025, we forecast $515.3 million, $46.8 million, and $0.58, respectively. For 2026, our revenue, EBITDA, and EPS estimates are also unchanged at $636.7 million, $59.4 million, and $0.76, respectively.
InPlay Oil (IPOOF/$12.46 | Price Target: $17) Mark Reichman [email protected] | (561) 999-2272 Hans Baldau [email protected] | Pembina Assets Shine, Disciplined Outlook Rating: OUTPERFORM
2025 financial results. InPlay Oil reported full-year 2025 adjusted funds flow (AFF) of C$114.4 million, or C$4.68 per share, above our estimate of C$112.9 million, or C$4.58 per share. Revenue for the year totaled C$291.4 million, ahead of our C$290.6 million forecast, as stronger Q4 production of 19,589 boe/d exceeded our estimate of 19,419 boe/d, in addition to stronger than expected AECO pricing. Full-year production averaged 17,043 boe/d, slightly above our 17,000 boe/d estimate.
Updated 2026 estimates. In the first quarter of 2026, we expect now revenues of C$79.9 million, AFF of C$27.4 million, and AFF per share of C$0.98, compared to prior estimates of C$79.0 million, C$26.6 million, and C$0.95, respectively. For the full-year 2026, we now estimate revenues of C$340.1 million, AFF of C$126.7 million, and AFF per share of C$4.53, up from C$340.1 million, C$125.2 million, and C$4.45. We are maintaining our production estimate of 18,605 boe/d in the first quarter and 18,900 boe/d for the year. These estimates are reflective of slightly higher commodity pricing.
Noble Capital Markets Research Report Thursday, March 5, 2026
Companies contained in today’s report:
First Phosphate Corp. (FRSPF)/OUTPERFORM – Gaining Government Support and Commercial Momentum NN (NNBR)/OUTPERFORM – First Look: 4Q25 and Full Year 2025 Results Ocugen (OCGN)/OUTPERFORM – FY2025 Reported With All Three Clinical Trials On Schedule
First Phosphate Corp. (FRSPF/$0.76 | Price Target: $1.65) Mark Reichman [email protected] | (561) 999-2272 Hans Baldau [email protected] | Gaining Government Support and Commercial Momentum Rating: OUTPERFORM
Canadian government steps up with financial support. First Phosphate received conditional approval for up to C$16.7 million in non-repayable funding through Natural Resources Canada under the Global Partnerships Initiative. The contribution will fund the assessment of technical and engineering parameters, including processing circuits and equipment, needed to validate the company’s ability to produce battery-grade phosphate concentrate aligned with its definitive offtake agreement. The funding supports study activities through 2028. First Phosphate received US$523,017 under a long-term phosphate concentrate offtake agreement, reinforcing commercial validation and establishing initial cash flow tied to downstream demand.
Phosphate added to Canada’s critical minerals list. The Canadian federal government amended the 2025 budget to include phosphate as a critical mineral essential for clean technology. This designation makes First Phosphate eligible for the 30% Critical Mineral Exploration Tax Credit (CMETC) and the 30% Clean Technology Manufacturing Investment Tax Credit (CTM). The CMETC enhances the company’s ability to raise exploration capital, while the CTM offers the potential to materially reduce downstream capital intensity for the planned phosphoric acid and LFP cathode active material facilities.
NN (NNBR/$1.53 | Price Target: $6) Joe Gomes [email protected] | 561-999-2262 First Look: 4Q25 and Full Year 2025 Results Rating: OUTPERFORM
Overview. For the full year 2025, NN delivered a third consecutive year of improved financial performance, although 4Q25 results were modestly below our expectations. Importantly, NN completed the most capital-intensive portion of its transformation plan that included plant closures, significant headcount realignment, and exiting dilutive business. As a result, NN enters 2026 as a healthier, leaner, and more focused company, performing on multiple fronts, which should result in the next chapter of net sales growth.
4Q25 Results. Sales in 4Q25 were $104.7 million, down 1.7% y-o-y, primarily due to rationalization of underperforming business and plants and lower volumes. Adjusted EBITDA for the fourth quarter of 2025 was $12.9 million, or 12.3% of sales, compared to $12.1 million, or 11.3% of sales, for the same period of 2024. Adjusted net loss for the fourth quarter of 2025 was $0.1 million, or $0.00 per diluted share, compared to adjusted net loss of $0.9 million, or $0.02 per share, in 4Q24. We had estimated $107.5 million, $14.5 million, and $0.04, respectively.
Ocugen (OCGN/$1.96 | Price Target: $8) Robert LeBoyer [email protected] | (212) 896-4625 FY2025 Reported With All Three Clinical Trials On Schedule Rating: OUTPERFORM
FY2026 Reported With Important Milestones Ahead. Ocugen reported a loss for 4Q25 of $17.7 million or $(0.06) per share, with a FY2025 loss of $67.8 million or $(0.23) per share. Cash on December 31, 2025, was $18.6 million, not including $22.5 million from a common stock offering in January 2026. Importantly, the company confirmed several clinical trial milestones had been achieved or were on schedule for announcement later in 2026. This maintains the goal of submitting three BLAs for three products during the next three years.
Topline Data From OCU400 Expected In March 2027. The Phase 3 liMeliGhT trial testing OCU400 for retinitis pigmentosa (RP) has completed enrollment. The patients have a 1-year evaluation after treatment, with top-line data expected during March 2027. Ocugen plans to begin a rolling BLA submission with the Manufacturing and Preclinical Data sections later in 2026. The Phase 3 data and clinical sections are expected to be filed shortly after the final analysis. The full filing is expected to be completed in 1Q27. We anticipate 6-month review, with FDA approval received in Fall 2027.
USA Rare Earth (Nasdaq: USAR) announced this morning a definitive agreement to acquire 100% of Serra Verde Group — owner of the Pela Ema rare earth mine and processing plant in Goiás, Brazil — in a transaction valued at approximately $2.8 billion. The deal is structured as $300 million in cash plus 126.849 million newly issued shares of USAR common stock, based on the company’s April 17 closing price of $19.95.
The acquisition is expected to close in the third quarter of 2026, pending regulatory approvals and customary closing conditions.
This is not a routine tuck-in. It is one of the most strategically significant critical minerals transactions to emerge from the Western world in years — and the timing is deliberate.
Serra Verde’s Pela Ema operation holds a distinction that very few assets in the world can claim: it is the only scaled producer outside of Asia capable of supplying all four magnetic rare earth elements — Neodymium (Nd), Praseodymium (Pr), Dysprosium (Dy), and Terbium (Tb) — at meaningful commercial volumes. These are the materials that go into permanent magnets, which in turn power electric vehicle motors, wind turbines, defense systems, and advanced electronics. China currently controls the overwhelming majority of global rare earth production and processing. Serra Verde represents a direct challenge to that dominance.
The operation is fully permitted and entered production in 2024 after more than $1.1 billion in capital investment. At Phase 1 nameplate capacity — expected to be reached by the end of 2027 — the mine is projected to produce approximately 6,400 metric tons of total rare earth oxide per year and generate annualized EBITDA of $550 to $650 million. The combined company is targeting approximately $1.8 billion in EBITDA by 2030.
The financial structure of this deal is notable beyond the headline price. Serra Verde has already secured a $565 million financing package from the U.S. International Development Finance Corporation to fund optimization and expansion through to positive cash flow. It has also locked in a 15-year, 100% offtake agreement with a special purpose vehicle capitalized by various U.S. government agencies and private capital sources — with guaranteed minimum floor prices for each of the four magnetic rare earths. That government-backed revenue floor substantially de-risks the asset and signals how seriously Washington views rare earth supply chain security as a national priority.
By end of 2027, Serra Verde’s output is expected to represent more than 50% of total non-China heavy rare earth supply globally — a figure that underscores just how critical this asset is to Western supply chain independence.
For USAR, the transaction adds Serra Verde leadership to its board, including Chairman Sir Mick Davis and CEO Thras Moraitis, who will also become President of the combined company. Pro-forma liquidity for the combined entity stands at approximately $3.2 billion.
Moelis & Company acted as exclusive financial advisor to USA Rare Earth. Goldman Sachs advised Serra Verde.
For small-cap investors tracking the critical minerals space, this is the deal that has been anticipated for years — and it closed on one of the most strategically defensible assets available outside of China.
Biotech’s long IPO drought may finally be breaking — but don’t mistake a crack in the window for a wide-open door.
This week, two biopharma companies launched roadshows that signal a cautious return of investor appetite to the public markets. GLP-1 developer Kailera Therapeutics hit the road at a $1.9 billion valuation, while proteomics company Alamar Biosciences priced at $17 per share — the top of its marketed range — and opened trading on the Nasdaq Friday with a 33% pop, valuing the company at roughly $1.53 billion. The upsized offering raised $191.3 million, a meaningful signal that institutional demand is real, not manufactured.
But the story isn’t really about IPOs. It’s about M&A.
The primary engine driving this biotech resurgence is an aggressive acquisition cycle fueled by the pharmaceutical industry’s looming patent cliff. Major drug companies are racing to backfill pipelines before blockbuster drugs lose exclusivity, and that urgency is translating into deal flow at a historic pace. According to a Stifel report, 19 biopharma M&A transactions of $1 billion or more were announced between January 1 and April 7 alone — putting the industry on pace for its second-highest annual total ever. Marquee deals include Merck’s $6.7 billion acquisition of Terns Pharmaceuticals and Eli Lilly’s $6.3 billion upfront commitment for Centessa Pharmaceuticals, both announced last month.
That M&A velocity matters beyond the deal itself. When large acquisitions close, venture investors recycle that capital back into the ecosystem — funding the next generation of companies and, critically, making investors more willing to participate in secondary offerings and IPOs. It’s a flywheel, and right now it’s spinning.
Valuations in the private markets are reflecting it. Median pre-money valuations for venture-growth biopharma companies jumped from $65 million to $247 million in 2025, according to PitchBook’s Q4 2025 Biopharma VC Trends report. And the Russell 2000 Biotech Index is up 9.7% year-to-date, outperforming the S&P 500.
That said, the numbers tell a sobering parallel story: of the six biopharma companies that have gone public since January, four are currently trading below their offer price. The market is rewarding quality — and punishing everyone else.
The threshold to go public has risen considerably since the 2020–2021 boom years, when companies with minimal patient data could attract institutional money. Today, clinical-stage companies are bringing 50 or more patients’ worth of data to the roadshow. Pre-clinical companies aren’t even in the conversation.
For small and microcap investors, this environment requires nuance. The biotech IPO window is open — but narrowly, and selectively. Companies that are scientifically de-risked, operationally sound, and well-positioned relative to M&A comps are getting deals done. Everything else is waiting.
The broader implication: as Big Pharma’s acquisition appetite grows, smaller biotech names that could plausibly become targets deserve a closer look. The deals are getting done — the question is who’s next on the list.
Onvansertib in combination with trastuzumab deruxtecan demonstrated enhanced antitumor activity, including tumor regression and apoptosis in HER2-low breast cancer models, supporting its potential for patients with limited treatment options
SAN DIEGO, Calif., April 17, 2026 (GLOBE NEWSWIRE) — Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, will present new preclinical data in a poster at the American Association for Cancer Research (AACR) Annual Meeting 2026, taking place April 17–22 in San Diego, California. These data highlight the potential of Cardiff’s highly specific oral PLK1 inhibitor, onvansertib, in combination with the HER2-targeted antibody-drug conjugate (ADC), trastuzumab deruxtecan (T-DXd), demonstrating robust antitumor activity and the ability to overcome resistance in HER2-low breast cancer models.
“These preclinical findings highlight a potential new opportunity for onvansertib, demonstrating its ability to enhance the activity of ADCs, which are becoming mainstays in oncology across multiple indications,” said Tod Smeal, Ph.D., Chief Scientific Officer of Cardiff Oncology. “By enhancing and prolonging DNA damage, this combination appears to drive greater apoptosis than either agent alone, offering a promising new approach for patients whose cancers have become resistant to standard-of-care treatments.”
Poster Presentation Highlights:
Onvansertib + T-DXd synergistically inhibited the viability of HER2-low breast cancer cell lines, including fulvestrant- and CDK4/6i-resistant cells
In the resistant triple-negative breast cancer model and two hormone receptor-positive models, the combination drove tumor regression in nearly all mice, with complete response rates up to 62%
Increased tumor regression, improved tumor growth inhibition, and extended event-free survival across models
Combination showed favorable tolerability in vivo
Following the presentation on April 19, 2026 from 2:00–5:00 PM PT, the poster titled “PLK1 inhibitor onvansertib potentiates the antitumor efficacy of trastuzumab deruxtecan (T-DXd) and reverses its resistance in therapy-resistant HER2-low breast cancer models” will be available on the Scientific Publications page of the Company’s website.
About Onvansertib Onvansertib is a highly specific, oral PLK1 inhibitor currently in mid-stage clinical development for RAS-mutated metastatic colorectal cancer. It is also being evaluated in multiple other cancers through investigator-initiated studies, including metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), triple-negative breast cancer (TNBC), and chronic myelomonocytic leukemia (CMML).
About Cardiff Oncology, Inc. Cardiff Oncology is a clinical-stage biotechnology company advancing innovative cancer treatments focused on PLK1 inhibition, a validated oncology target with practice-changing potential. Our lead asset, onvansertib, is a highly specific, oral PLK1 inhibitor currently being evaluated in a Phase 2 trial for first-line treatment of RAS-mutated metastatic colorectal cancer (mCRC), addressing a large, underserved patient population with high unmet need. Onvansertib is also under investigation in other PLK1-driven cancers through ongoing investigator-initiated trials and has shown robust single agent clinical activity in hard-to-treat tumors. By targeting tumor vulnerabilities, we aim to overcome treatment resistance and deliver improved clinical outcomes for patients.
Forward-Looking Statements Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified using words such as “anticipate,” “believe,” “forecast,” “estimated” and “intend” or other similar terms or expressions that concern Cardiff Oncology’s expectations, strategy, plans or intentions. These forward-looking statements are based on Cardiff Oncology’s current expectations and actual results could differ materially. There are several factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, clinical trials involve a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results; our clinical trials may be suspended or discontinued due to unexpected side effects or other safety risks that could preclude approval of our product candidate; results of preclinical studies or clinical trials for our product candidate could be unfavorable or delayed; our need for additional financing; risks related to business interruptions, including the outbreak of COVID-19 coronavirus and cyber-attacks on our information technology infrastructure, which could seriously harm our financial condition and increase our costs and expenses; uncertainties of government or third party payer reimbursement; dependence on key personnel; limited experience in marketing and sales; substantial competition; uncertainties of patent protection and litigation; dependence upon third parties; and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations. There are no guarantees that our product candidate will be utilized or prove to be commercially successful. Additionally, there are no guarantees that future clinical trials will be completed or successful or that our product candidate will receive regulatory approval for any indication or prove to be commercially successful. Investors should read the risk factors set forth in Cardiff Oncology’s Form 10-K for the year ended December 31, 2025, and other periodic reports filed with the Securities and Exchange Commission. While the list of factors presented here is considered representative, no such list should be considered to be a complete statement of all potential risks and uncertainties. Unlisted factors may present significant additional obstacles to the realization of forward-looking statements. Forward-looking statements included herein are made as of the date hereof, and Cardiff Oncology does not undertake any obligation to update publicly such statements to reflect subsequent events or circumstances.
Oil markets were thrown into a volatile session Friday morning after Iran’s foreign minister declared the Strait of Hormuz fully open to commercial traffic for the duration of a fragile 10-day ceasefire between Israel and Lebanon — sending crude prices into a sharp, double-digit freefall.
Brent crude dropped 10%, falling below $90 per barrel, while West Texas Intermediate slid more than 10.5%, pulling below $82. Both benchmarks had opened the week above $100, meaning the week’s loss alone represents one of the most dramatic oil price collapses in recent memory.
The swift selloff reflects just how much of the oil market’s recent premium was baked in around fears of a sustained Strait of Hormuz closure. The strait is the world’s most critical chokepoint for global energy flows, with roughly 20% of all seaborne oil passing through its narrow passage daily. Even a partial disruption sends shockwaves through energy markets — and traders had been pricing in exactly that risk.
The announcement comes as a direct byproduct of the Israel-Lebanon ceasefire that took effect Thursday evening. With that front temporarily cooling, Tehran signaled it could ease its stranglehold on one of the most strategically sensitive waterways on the planet. On the surface, that’s a significant de-escalation.
But energy markets shouldn’t pop the champagne just yet.
Iranian state media clarified Friday that any vessel seeking passage must coordinate directly with the Revolutionary Guard Corps — a requirement that carries its own practical and geopolitical complications for commercial shipowners. It also remained unclear which specific route Iran expects vessels to use, a sticking point that emerged after Iran previously insisted ships pass close to the Iranian coast rather than through more neutral Omani waters.
Adding to the confusion, President Trump posted shortly after the Iranian announcement that while the strait is open, the U.S. naval blockade targeting Iran specifically will remain in full force until a broader deal is finalized. That dual reality — technically open waters but an active American naval presence — leaves shipowners navigating a legal and logistical gray area.
The bigger picture here is a potential U.S.-Iran deal that’s reportedly taking shape. According to reports Friday, Washington is considering a framework that would release roughly $20 billion in frozen Iranian assets in exchange for Iran surrendering its stockpile of enriched uranium. Trump told reporters a deal was looking favorable and that a second round of negotiations could begin as early as this weekend.
For energy investors and small-cap companies with exposure to oil services, exploration, or transportation, Friday’s move is a reminder of how quickly geopolitical sentiment can reprice an entire sector. The energy trade that dominated the first quarter — long crude on Middle East risk — just took a serious gut punch.
Watch the second round of talks carefully. If a deal materializes, energy markets could reprice even further. If talks collapse, expect crude to snap back hard.
